Boron-Containing heterocycles as promising pharmacological agents
[Display omitted] The incorporation of the “magic” boron atom has been established as an important new strategy in the field of medicinal chemistry as boron compounds have been shown to form various bonds with their biological targets. Currently, a number of boron-based drugs (e.g. bortezomib, crisa...
Saved in:
| Published in | Bioorganic & medicinal chemistry Vol. 63; p. 116748 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.06.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | [Display omitted]
The incorporation of the “magic” boron atom has been established as an important new strategy in the field of medicinal chemistry as boron compounds have been shown to form various bonds with their biological targets. Currently, a number of boron-based drugs (e.g. bortezomib, crisaborole, and tavaborole) have been FDA approved and are in the clinic, and several other boron-containing compounds are in clinical trials. Boron-based heterocycles have an incredible potential in the ongoing quest for new therapeutic agents owing to their plethora of biological activities and useful pharmacokinetic profiles. The present perspective is intended to review the pharmacological applications of boron-based heterocycles that have been published. We have classified these compounds into groups exhibiting shared pharmacological activities and discussed their corresponding biological targets focusing mainly on the most potent therapeutic compounds. |
|---|---|
| AbstractList | [Display omitted]
The incorporation of the “magic” boron atom has been established as an important new strategy in the field of medicinal chemistry as boron compounds have been shown to form various bonds with their biological targets. Currently, a number of boron-based drugs (e.g. bortezomib, crisaborole, and tavaborole) have been FDA approved and are in the clinic, and several other boron-containing compounds are in clinical trials. Boron-based heterocycles have an incredible potential in the ongoing quest for new therapeutic agents owing to their plethora of biological activities and useful pharmacokinetic profiles. The present perspective is intended to review the pharmacological applications of boron-based heterocycles that have been published. We have classified these compounds into groups exhibiting shared pharmacological activities and discussed their corresponding biological targets focusing mainly on the most potent therapeutic compounds. The incorporation of the "magic" boron atom has been established as an important new strategy in the field of medicinal chemistry as boron compounds have been shown to form various bonds with their biological targets. Currently, a number of boron-based drugs (e.g. bortezomib, crisaborole, and tavaborole) have been FDA approved and are in the clinic, and several other boron-containing compounds are in clinical trials. Boron-based heterocycles have an incredible potential in the ongoing quest for new therapeutic agents owing to their plethora of biological activities and useful pharmacokinetic profiles. The present perspective is intended to review the pharmacological applications of boron-based heterocycles that have been published. We have classified these compounds into groups exhibiting shared pharmacological activities and discussed their corresponding biological targets focusing mainly on the most potent therapeutic compounds. |
| ArticleNumber | 116748 |
| Author | Saito, Mariko Weiss, Louis M. Das, Sasmita Adil Shareef, Mohammed Nandwana, Nitesh K. Das, Bhaskar C. Das, Yogarupa |
| Author_xml | – sequence: 1 givenname: Bhaskar C. surname: Das fullname: Das, Bhaskar C. email: Bhaskar.Das@liu.edu organization: Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA – sequence: 2 givenname: Mohammed surname: Adil Shareef fullname: Adil Shareef, Mohammed organization: Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA – sequence: 3 givenname: Sasmita surname: Das fullname: Das, Sasmita organization: Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA – sequence: 4 givenname: Nitesh K. surname: Nandwana fullname: Nandwana, Nitesh K. organization: Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA – sequence: 5 givenname: Yogarupa surname: Das fullname: Das, Yogarupa organization: Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA – sequence: 6 givenname: Mariko surname: Saito fullname: Saito, Mariko organization: Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY 10962, USA – sequence: 7 givenname: Louis M. surname: Weiss fullname: Weiss, Louis M. organization: Department of Medicine, Division of Infectious Diseases and Department of Pathology Division of Parasitology and Tropical Medicine, Albert Einstein College of Medicine, Bronx NY-10461, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35453036$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kD1PwzAQhi1URD_gB7CgjCwpPttxEjGVii-pEgvMlutcWleJXewUqf-eVAFGphvueV_dPVMyct4hIddA50BB3u3m69bMGWVsDiBzUZyRCQgpUs5LGJEJLWWR0qKUYzKNcUcpZaKECzLmmcg45XJCFg8-eJcuveu0ddZtki12GLw5mgZjomOyD7618bTZb3VotfGN31ijm0Rv0HXxkpzXuol49TNn5OPp8X35kq7enl-Xi1VqeMa7tMo4cMC8MgJYmWlWC51JLWqUNGO8lkVe1WsAjhoLKbTGKmc5oxwrBgUCn5Hbobc_6POAsVP9WQabRjv0h6iYzAQruRRFj8KAmuBjDFirfbCtDkcFVJ3MqZ3qzamTOTWY6zM3P_WHdYvVX-JXVQ_cDwD2T35ZDCoai85gZQOaTlXe_lP_DbFYf_A |
| CitedBy_id | crossref_primary_10_1016_j_bmcl_2023_129330 crossref_primary_10_3390_inorganics11010034 crossref_primary_10_1021_acs_chemrev_3c00663 crossref_primary_10_1016_j_bmcl_2022_128864 crossref_primary_10_1016_j_bioorg_2023_106390 crossref_primary_10_1038_s41573_022_00542_z crossref_primary_10_1021_acs_jmedchem_3c01194 crossref_primary_10_1016_j_bioorg_2023_106976 crossref_primary_10_1080_17460441_2023_2153829 crossref_primary_10_1089_cbr_2022_0060 crossref_primary_10_1016_j_ejmech_2023_115761 crossref_primary_10_1021_acscatal_3c05766 crossref_primary_10_1039_D3DT03826B crossref_primary_10_3390_molecules27113402 crossref_primary_10_1002_ange_202301463 crossref_primary_10_3390_molecules27113427 crossref_primary_10_4239_wjd_v15_i6_1060 crossref_primary_10_1016_j_rechem_2024_101493 crossref_primary_10_3390_molecules28031052 crossref_primary_10_3390_inorganics11020070 crossref_primary_10_1016_j_ccr_2023_215254 crossref_primary_10_1002_slct_202303410 crossref_primary_10_1039_D3CP01037F crossref_primary_10_1016_j_bmc_2022_117071 crossref_primary_10_1021_jacs_4c06360 crossref_primary_10_1002_chem_202203345 crossref_primary_10_1002_slct_202205003 crossref_primary_10_1016_j_pharmthera_2023_108548 crossref_primary_10_1002_anie_202301463 crossref_primary_10_1021_acs_jmedchem_3c00433 crossref_primary_10_1039_D2RA05063C |
| Cites_doi | 10.1016/j.bmc.2016.05.058 10.1128/AAC.01205-17 10.1177/107327480301000502 10.1002/cbdv.201400007 10.4155/fmc.09.71 10.1016/j.bmcl.2016.04.093 10.1021/jm049899b 10.1016/j.bmc.2019.115236 10.1371/journal.pntd.0001151 10.1016/j.tetlet.2020.152667 10.1021/acs.jmedchem.9b01518 10.1007/s40262-018-0702-1 10.1039/C8OB00998H 10.1124/jpet.116.232819 10.1517/13543784.16.9.1459 10.1080/17425255.2018.1511702 10.1016/j.bmcl.2016.10.024 10.1039/D0RA07767D 10.1039/C8SC05167D 10.1016/S0960-894X(98)00126-7 10.1002/med.10043 10.1002/ejoc.201700989 10.1016/j.bmcl.2009.03.007 10.1021/acsmedchemlett.7b00369 10.1071/CH14534 10.1021/acs.jmedchem.9b01976 10.1080/14756366.2017.1414808 10.1021/acsmedchemlett.0c00403 10.1016/j.bioorg.2015.05.004 10.1371/journal.pntd.0006450 10.1128/AAC.01053-21 10.26508/lsa.201800025 10.1111/cbdd.13496 10.1016/j.molstruc.2019.01.018 10.1021/acsomega.8b00702 10.1016/j.febslet.2012.07.058 10.1002/cmdc.201700731 10.2174/1568026611107011301 10.1002/cbdv.200890206 10.3390/antibiotics10080995 10.1016/j.ejmech.2019.06.092 10.1021/acs.jmedchem.5b01088 10.1039/C7MD00552K 10.1016/j.bmcl.2016.06.049 10.1021/acs.jmedchem.9b00736 10.1517/14656566.2014.921158 10.1016/j.bcp.2016.09.025 10.1021/acs.jmedchem.7b00631 10.1080/13543776.2018.1473379 10.1002/cmdc.201700047 10.1007/s40265-014-0276-7 10.1016/j.jorganchem.2020.121268 10.1016/j.bmcl.2017.11.028 10.1038/ja.2016.34 10.1128/AAC.01987-17 10.1128/CMR.00037-09 10.1016/j.ejmech.2017.06.049 10.1107/S0907444996005458 10.1021/acs.jmedchem.7b00621 10.1093/jnci/djq174 10.4155/fmc.13.38 10.1080/14787210.2020.1756775 10.1126/science.1142189 10.1021/jm00374a003 10.1128/AAC.00568-16 10.1128/AAC.49.12.4821-4833.2005 10.1016/j.tet.2016.03.038 10.3389/fphar.2020.01328 10.1006/jmbi.2001.4643 10.1016/j.bmc.2007.11.032 10.1128/MCB.24.14.6476-6487.2004 10.1016/j.chembiol.2017.08.011 10.1139/cjc-2018-0108 10.1007/s00280-010-1283-3 10.1371/journal.pone.0239354 10.1021/acs.chemrev.8b00561 10.1016/j.ijantimicag.2005.08.018 10.1021/acs.jmedchem.5b00127 10.1016/j.apsb.2021.01.010 10.1016/j.bmc.2015.06.019 10.1128/AAC.00820-16 10.1128/AAC.02122-18 10.1111/bcp.14208 10.3389/fmicb.2019.02473 10.1177/8755122519844507 10.1021/acsinfecdis.5b00031 10.1128/AAC.02058-12 10.1073/pnas.1807915115 10.3389/fimmu.2019.02538 10.1007/s10637-018-0611-z 10.1016/j.ejphar.2019.04.020 10.1107/S2053230X15022098 10.3390/molecules23082038 10.1016/S1470-2045(14)71125-8 10.1016/j.jorganchem.2015.06.021 10.1002/hc.21363 10.1358/dot.2017.53.4.2604174 10.1038/sj.leu.2404528 10.1021/jm400317w 10.1016/j.beem.2009.03.004 10.1016/j.bmcl.2018.10.032 10.1021/acsinfecdis.9b00396 10.5070/D3205022608 10.1080/14756366.2016.1261129 10.1126/science.274.5295.2107 10.1016/j.bmc.2012.11.055 10.1070/RCR4977 10.1016/j.lfs.2006.11.034 10.1016/j.chembiol.2007.04.009 10.1128/AAC.02419-17 10.1016/j.ejmech.2014.04.079 10.1517/13543784.16.2.157 10.1038/srep02475 10.1021/acs.jmedchem.5b00341 10.1021/acsmedchemlett.9b00252 10.1093/jac/dkaa391 10.1038/ncomms14574 10.1055/s-2007-973886 10.1016/j.tube.2017.11.003 10.1074/jbc.274.43.30811 10.1039/C7RA03266H 10.7547/16-154 10.1128/AAC.01963-19 10.1128/AAC.03774-14 10.1039/C8OB02668H 10.1021/cr010182v 10.1007/s00044-016-1603-1 10.1021/acs.joc.8b02269 10.1016/S1470-2045(11)70081-X |
| ContentType | Journal Article |
| Copyright | 2022 Elsevier Ltd Copyright © 2022 Elsevier Ltd. All rights reserved. |
| Copyright_xml | – notice: 2022 Elsevier Ltd – notice: Copyright © 2022 Elsevier Ltd. All rights reserved. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| DOI | 10.1016/j.bmc.2022.116748 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology Chemistry |
| EISSN | 1464-3391 |
| EndPage | 116748 |
| ExternalDocumentID | 10_1016_j_bmc_2022_116748 35453036 S0968089622001407 |
| Genre | Journal Article Review Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAAA NIH HHS grantid: R21 AA027374 – fundername: NIAID NIH HHS grantid: R01 AI132614 – fundername: NINDS NIH HHS grantid: R01 NS109423 |
| GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 23N 4.4 457 4G. 5GY 5VS 7-5 71M 8P~ 9JM 9JN AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AARLI AATCM AAXUO ABBQC ABFNM ABGSF ABJNI ABLVK ABMAC ABMZM ABUDA ABYKQ ABZDS ACDAQ ACGFS ACIUM ACRLP ADBBV ADECG ADEZE ADUVX AEBSH AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AFZHZ AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AJSZI ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BLXMC BNPGV CS3 DOVZS DU5 EBS EFJIC EFLBG EO8 EO9 EP2 EP3 F5P FDB FIRID FLBIZ FNPLU FYGXN G-Q GBLVA IHE J1W KOM LCYCR LZ2 M29 M2Z M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OZT P-8 P-9 P2P PC. Q38 ROL RPZ SCC SDF SDG SDP SES SPC SPCBC SSH SSK SSP SSU SSZ T5K UPT XPP YK3 ~02 ~G- AAXKI AKRWK CGR CUY CVF ECM EIF NPM RIG 53G AAQXK AAYXX ABXDB ACNNM ACRPL ADMUD ADNMO AFFNX AFJKZ AGHFR AGRDE AHHHB ASPBG AVWKF AZFZN CITATION EJD FEDTE FGOYB G-2 HEA HMK HMO HMS HMT HVGLF HZ~ R2- SAE SCB SEW SOC SPT WUQ ZMT 7X8 |
| ID | FETCH-LOGICAL-c353t-d53131e7dc41295a2f4a56a4fe60523f687dfb113eae864aaed727203ed218e13 |
| IEDL.DBID | AIKHN |
| ISSN | 0968-0896 |
| IngestDate | Wed Dec 04 14:04:09 EST 2024 Fri Dec 06 01:19:15 EST 2024 Sat Sep 28 08:40:38 EDT 2024 Fri Feb 23 02:39:08 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Benzoxaboroles Diazaborines Boron Containing Heterocycles Oxazoborolidine-ones Boron containing Drugs Pharmacological agents Oxadiazaboroles Oxazaborolidines Azaborines |
| Language | English |
| License | Copyright © 2022 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c353t-d53131e7dc41295a2f4a56a4fe60523f687dfb113eae864aaed727203ed218e13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-2 |
| PMID | 35453036 |
| PQID | 2654293648 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | proquest_miscellaneous_2654293648 crossref_primary_10_1016_j_bmc_2022_116748 pubmed_primary_35453036 elsevier_sciencedirect_doi_10_1016_j_bmc_2022_116748 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-06-01 2022-06-00 20220601 |
| PublicationDateYYYYMMDD | 2022-06-01 |
| PublicationDate_xml | – month: 06 year: 2022 text: 2022-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Bioorganic & medicinal chemistry |
| PublicationTitleAlternate | Bioorg Med Chem |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd |
| Publisher_xml | – name: Elsevier Ltd |
| References | I. Millennium Pharmaceuticals, VELCADE®(bortezomib) for injection prescribing information, Rev, 2004. Hecker, Reddy, Totrov (b0095) 2015; 58 Zahid, Li, Kombe (b0460) 2019; 10 H.o.p. information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021602s040lbl.pdf, 2003. Bonardi, Nocentini, Cadoni (b0515) 2020; 11 Zhao, Nettleton, Karki (b0440) 2017; 12 Moreau, Pylypenko, Grosicki (b0165) 2011; 12 Rombouts, Tovar, Austin (b0430) 2015; 58 Tevyashova, Chudinov (b0040) 2021; 90 Alam, Arora, Gurrapu (b0570) 2016; 72 Zhang, Zhang, Hao (b0650) 2019; 62 Yang, Johnson, Letourneau (b0370) 2014; 68 Golovanov, Sukhorukov (b0045) 2021; 379 Caselli, Romagnoli, Vahabi (b0725) 2015; 58 Jabbour, Steinberg, Dembitsky (b0385) 2004; 47 Zhang, Plattner, Easom (b0740) 2016; 26 Meany, Balis, Aikin (b0270) 2010; 102 Lei, Feng, Bai (b0575) 2019; 17 Vlasceanu, Jessing, Kilburn (b0435) 2015; 23 Richardson, Baz, Wang (b0180) 2014; 124 Paton (b0200) 2017; 53 Boghi, Hall (b0380) 2018; 16 Velasco-Bejarano, Trujillo-Ferrara, Miranda (b0410) 2007; 2007 https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204427s000lbl.pdf, 2014. Ren, Shi, Zhao (b0675) 2020; 28 Jordan, Sandoval, Serobyan (b0310) 2015; 71 Accardi, Toscani, Bolzoni (b0080) 2015 Roujeinikova, Sedelnikova, de Boer (b0295) 1999; 274 Cunningham (b0155) 2007; 16 Brackman, Al Quntar, Enk (b0765) 2013; 21 Baldwin, Rivers-Auty, Daniels (b0465) 2017; 24 Baldock, Rafferty, Sedelnikova (b0290) 1996; 52 Hicks, Kyle, Vogels (b0365) 2008; 5 Nazarian, Weinberg (b0145) 2009; 10 Hurdle, O'Neill, Chopra (b0525) 2005; 49 Nocentini, Cadoni, Del Prete (b0595) 2017; 8 Scott, Veinot, Stack (b0315) 2018; 96 Voorhees, Dees, O’Neil (b0065) 2003; 9 Kumar, Rao, Purnapatre (b0550) 2019; 63 Krzyżek (b0395) 2019; 10 Hu, Liu, Fang (b0615) 2013; 3 Lapa, Mirchink, Isakova (b0585) 2017; 32 Haney, Schrank, Wuest (b0450) 2021; 62 Santos, Pinhanelli, Garcia (b0670) 2017; 138 Pertschy, Zisser, Schein (b0360) 2004; 24 Mushtaq, Vickers, Doumith, Ellington, Woodford, Livermore (b0090) 2021; 76 Steketee, Vincent, Achcar (b0705) 2018; 12 Fernandes, Denny, Dos Santos (b0025) 2019; 179 Nocentini, Supuran, Winum (b0035) 2018; 28 Arrington, Barcan, Calandra (b0645) 2018; 84 Moustafa, Feldman (b0140) 2014; 20 Lomovskaya, Tsivkovski, Nelson (b0105) 2020; 64 Rubino, Bhavnani, Loutit (b0235) 2018; 62 Powers, Asgian, Ekici (b0325) 2002; 102 Reece, Sullivan, Lonial (b0160) 2011; 67 Das, Nandwana, Ojha (b0050) 2022; 153657 Buchtele N, Schwameis M, Schoergenhofer C. Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose-escalating trial 2020;86:979-990. Psurski, Łupicka-Słowik, Adamczyk-Woźniak (b0655) 2019; 37 Sanchorawala, Palladini, Kukreti (b0190) 2017; 130 Aharoni, Bronstheyn, Jabbour (b0400) 2008; 16 Al-Zoubi, Al-Zoubi, Jaradat (b0530) 2017; 2017 McKinney, Zhou, Eyermann (b0520) 2015; 1 Baldock, Rafferty, Sedelnikova (b0285) 1996; 274 Rock, Mao, Yaremchuk (b0125) 2007 Kilic, Savci, Alan, Beyazsakal (b0480) 2020; 917 Davis, Franzblau, Martin (b0345) 1998; 8 António, Gonçalves, Guedes (b0335) 2018; 3 Van Bocxlaer, Gaukel, Hauser (b0735) 2018; 62 Dong, Virtucio, Zemska (b0690) 2016; 358 Gupta, Hanley, Xia (b0175) 2019; 58 Velasco, Trujillo-Ferrara, Castillo (b0405) 2007; 80 Reddy, Trivedi, Kumar (b0485) 2016; 26 Jacobs, Plattner, Don (b0510) 2011; 11 Li, Hernandez, Rock (b0245) 2017; 60 Yang, Wang, Kouadir (b0455) 2019; 10 Akama, Freund, Berry (b0750) 2019; 6 Rosa, Rocha, Rodrigues (b0475) 2020; 11 Borys, Wieczorek, Tarkowska (b0625) 2020; 10 Raunio, Mannoja, Nguyen (b0415) 2017; 7 Elewski, Tosti (b0215) 2014; 15 Korkegian, O'Malley, Xia (b0560) 2018; 108 Akama, Baker, Zhang (b0500) 2009; 19 Kanichar, Roppiyakuda, Kosmowska (b0305) 2014; 11 Johnson (b0260) 2000; 11 Adamczyk-Woźniak, Cabaj, Dominiak (b0610) 2015; 60 Benowitz, Eberl, Erickson-Miller (b0685) 2018; 28 Richardson, Hideshima, Anderson (b0505) 2003; 10 Muz, Ghazarian, Ou (b0075) 2016; 10 Ward, Silva, Martinez (b0320) 2016; 24 Markham (b0210) 2014; 74 Suman, Patel, Kasibotla (b0660) 2015; 798 Nocentini, Cadoni, Dumy, Supuran, Winum (b0605) 2018; 33 Gronowitz, Dahlgren, Namtvedt (b0275) 1971; 8 Dowell, Dickerson, Henkel (b0240) 2021; 65 Levy, Baldock, Wallace (b0300) 2001; 309 Purnapatre, Rao, Pandya (b0545) 2018; 62 Baldwin, Tapia, Swanton (b0470) 2018; 13 Patel, O'Malley, Zhang (b0565) 2017; 61 Pir, Agirbas, Budak (b0760) 2017; 28 Nocentini, Supuran, Winum (b0490) 2018; 28 Légaré, Pranckevicius, Braunschweig (b0005) 2019; 119 Flint, Korkegian, Parish (b0355) 2020; 15 Jabbour, Srebnik, Zaks (b0390) 2005; 26 Yang, Zhu, Zhang (b0755) 2018; 9 Hamrick, Docquier, Uehara (b0110) 2020; 64 Alterio, Cadoni, Esposito (b0600) 2016; 52 Zhang, Yang, Qiao (b0665) 2016; 26 Wu, Zhang, Meng (b0745) 2014; 81 Song, Gao, Sun (b0015) 2021; 11 Tevyashova, Korolev, Trenin (b0635) 2016; 69 Baker, Ding, Akama (b0020) 2009; 1 Drawz, Bonomo (b0100) 2010; 23 Carcione, Siracusa, Sulejmani (b0085) 2021; 10 Yang, Gao, Wang (b0330) 2003; 23 Printsevskaya, Korolev, Isakova (b0590) 2016; 61 Sonoiki, Palencia, Guo (b0730) 2016; 60 Sonoiki, Ng, Lee (b0720) 2017; 8 Liu, Trout, Chu (b0115) 2020; 63 Hecker, Reddy, Lomovskaya (b0250) 2020; 63 Akama, Zhang, Freund (b0700) 2018; 28 Boknevitz, Italia, Li (b0445) 2019; 10 Larcher, Nocentini, Supuran (b0695) 2019; 10 Gumbo, Beteck, Mandizvo (b0555) 2018; 23 Ramirez (b0060) 2017; 8 Cambray, Bandyopadhyay, Gao (b0340) 2017; 53 O'Dwyer, Spivak, Ingraham (b0540) 2015; 59 Xia Y, Zhou Y, Carter DS et al. Discovery of a cofactor-independent inhibitor of Mycobacterium tuberculosis InhA 2018;1:e201800025. Rock, Mao, Yaremchuk (b0620) 2007; 316 Zhang, Plattner, Easom (b0715) 2017; 60 Maynard, Crosby, Ellis (b0640) 2014; 57 Bonvini, Zorzi, Basso (b0070) 2007; 21 Grassberger, Turnowsky, Hildebrandt (b0280) 1984; 27 Das, Thapa, Karki (b0010) 2013; 5 Highlights of prescribing information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207695s000lbl.pdf, 2016. McDowell, Olin (b0135) 2019; 35 Griffith, Loutit, Morgan (b0230) 2016; 60 Zhou, Nettles, Bruning (b0425) 2007; 14 Novelli, Del Giacomo, Rossolini (b0030) 2020; 18 Takeda Pharma A, Ninlaro S. European Public Assessment Report-Product Information, 2016. Kumar, Berdeja, Niesvizky (b0185) 2014; 15 Pir, Agirbas, Budak (b0375) 2016; 25 Wall, Rico, Lukac (b0710) 2018; 115 Thornberry, Gallwitz (b0150) 2009; 23 Alley, Baker, Beutner (b0120) 2007; 16 Markinson, Ghannoum, Winter (b0130) 2018; 108 Freund, Akama, Alley (b0495) 2012; 586 Jacobs, Nare, Wring (b0255) 2011; 5 Hernandez, Crépin, Palencia (b0535) 2013; 57 Burgos, Biagi, Rodvold (b0225) 2018; 14 Viswanathan, Sebastianelli, Brown (b0420) 2019; 854 Borys, Matuszewska, Wieczorek (b0630) 2019; 1181 Fernandes, Martens (b0580) 2017; 133 Natsutani, Iwata, Yamai (b0680) 2019; 93 Pir (10.1016/j.bmc.2022.116748_b0375) 2016; 25 Adamczyk-Woźniak (10.1016/j.bmc.2022.116748_b0610) 2015; 60 Wu (10.1016/j.bmc.2022.116748_b0745) 2014; 81 Kumar (10.1016/j.bmc.2022.116748_b0185) 2014; 15 Dowell (10.1016/j.bmc.2022.116748_b0240) 2021; 65 Yang (10.1016/j.bmc.2022.116748_b0455) 2019; 10 Griffith (10.1016/j.bmc.2022.116748_b0230) 2016; 60 Baldock (10.1016/j.bmc.2022.116748_b0285) 1996; 274 Grassberger (10.1016/j.bmc.2022.116748_b0280) 1984; 27 Akama (10.1016/j.bmc.2022.116748_b0500) 2009; 19 Jordan (10.1016/j.bmc.2022.116748_b0310) 2015; 71 Maynard (10.1016/j.bmc.2022.116748_b0640) 2014; 57 Baldock (10.1016/j.bmc.2022.116748_b0290) 1996; 52 Lei (10.1016/j.bmc.2022.116748_b0575) 2019; 17 Rock (10.1016/j.bmc.2022.116748_b0620) 2007; 316 Bonardi (10.1016/j.bmc.2022.116748_b0515) 2020; 11 Gumbo (10.1016/j.bmc.2022.116748_b0555) 2018; 23 Freund (10.1016/j.bmc.2022.116748_b0495) 2012; 586 Caselli (10.1016/j.bmc.2022.116748_b0725) 2015; 58 Powers (10.1016/j.bmc.2022.116748_b0325) 2002; 102 10.1016/j.bmc.2022.116748_b0170 McKinney (10.1016/j.bmc.2022.116748_b0520) 2015; 1 Zhang (10.1016/j.bmc.2022.116748_b0650) 2019; 62 Thornberry (10.1016/j.bmc.2022.116748_b0150) 2009; 23 Tevyashova (10.1016/j.bmc.2022.116748_b0635) 2016; 69 António (10.1016/j.bmc.2022.116748_b0335) 2018; 3 Steketee (10.1016/j.bmc.2022.116748_b0705) 2018; 12 10.1016/j.bmc.2022.116748_b0205 Jabbour (10.1016/j.bmc.2022.116748_b0390) 2005; 26 Zhao (10.1016/j.bmc.2022.116748_b0440) 2017; 12 Nocentini (10.1016/j.bmc.2022.116748_b0605) 2018; 33 Brackman (10.1016/j.bmc.2022.116748_b0765) 2013; 21 Yang (10.1016/j.bmc.2022.116748_b0330) 2003; 23 Alterio (10.1016/j.bmc.2022.116748_b0600) 2016; 52 Nocentini (10.1016/j.bmc.2022.116748_b0035) 2018; 28 Pertschy (10.1016/j.bmc.2022.116748_b0360) 2004; 24 Haney (10.1016/j.bmc.2022.116748_b0450) 2021; 62 Fernandes (10.1016/j.bmc.2022.116748_b0025) 2019; 179 Lomovskaya (10.1016/j.bmc.2022.116748_b0105) 2020; 64 Burgos (10.1016/j.bmc.2022.116748_b0225) 2018; 14 Fernandes (10.1016/j.bmc.2022.116748_b0580) 2017; 133 Accardi (10.1016/j.bmc.2022.116748_b0080) 2015 Larcher (10.1016/j.bmc.2022.116748_b0695) 2019; 10 Jacobs (10.1016/j.bmc.2022.116748_b0255) 2011; 5 Sonoiki (10.1016/j.bmc.2022.116748_b0730) 2016; 60 Carcione (10.1016/j.bmc.2022.116748_b0085) 2021; 10 Zhou (10.1016/j.bmc.2022.116748_b0425) 2007; 14 Zhang (10.1016/j.bmc.2022.116748_b0715) 2017; 60 Boknevitz (10.1016/j.bmc.2022.116748_b0445) 2019; 10 Voorhees (10.1016/j.bmc.2022.116748_b0065) 2003; 9 Meany (10.1016/j.bmc.2022.116748_b0270) 2010; 102 10.1016/j.bmc.2022.116748_b0055 Hernandez (10.1016/j.bmc.2022.116748_b0535) 2013; 57 Légaré (10.1016/j.bmc.2022.116748_b0005) 2019; 119 Rock (10.1016/j.bmc.2022.116748_b0125) 2007 Li (10.1016/j.bmc.2022.116748_b0245) 2017; 60 Bonvini (10.1016/j.bmc.2022.116748_b0070) 2007; 21 Krzyżek (10.1016/j.bmc.2022.116748_b0395) 2019; 10 10.1016/j.bmc.2022.116748_b0195 Psurski (10.1016/j.bmc.2022.116748_b0655) 2019; 37 Benowitz (10.1016/j.bmc.2022.116748_b0685) 2018; 28 Ramirez (10.1016/j.bmc.2022.116748_b0060) 2017; 8 Hurdle (10.1016/j.bmc.2022.116748_b0525) 2005; 49 Nocentini (10.1016/j.bmc.2022.116748_b0490) 2018; 28 Richardson (10.1016/j.bmc.2022.116748_b0505) 2003; 10 Moreau (10.1016/j.bmc.2022.116748_b0165) 2011; 12 Hicks (10.1016/j.bmc.2022.116748_b0365) 2008; 5 Kanichar (10.1016/j.bmc.2022.116748_b0305) 2014; 11 Viswanathan (10.1016/j.bmc.2022.116748_b0420) 2019; 854 Natsutani (10.1016/j.bmc.2022.116748_b0680) 2019; 93 Zhang (10.1016/j.bmc.2022.116748_b0740) 2016; 26 10.1016/j.bmc.2022.116748_b0220 Hecker (10.1016/j.bmc.2022.116748_b0250) 2020; 63 Muz (10.1016/j.bmc.2022.116748_b0075) 2016; 10 Elewski (10.1016/j.bmc.2022.116748_b0215) 2014; 15 Aharoni (10.1016/j.bmc.2022.116748_b0400) 2008; 16 Markham (10.1016/j.bmc.2022.116748_b0210) 2014; 74 Yang (10.1016/j.bmc.2022.116748_b0370) 2014; 68 Scott (10.1016/j.bmc.2022.116748_b0315) 2018; 96 Paton (10.1016/j.bmc.2022.116748_b0200) 2017; 53 Reddy (10.1016/j.bmc.2022.116748_b0485) 2016; 26 Vlasceanu (10.1016/j.bmc.2022.116748_b0435) 2015; 23 Printsevskaya (10.1016/j.bmc.2022.116748_b0590) 2016; 61 Sonoiki (10.1016/j.bmc.2022.116748_b0720) 2017; 8 Hecker (10.1016/j.bmc.2022.116748_b0095) 2015; 58 Jabbour (10.1016/j.bmc.2022.116748_b0385) 2004; 47 Yang (10.1016/j.bmc.2022.116748_b0755) 2018; 9 Pir (10.1016/j.bmc.2022.116748_b0760) 2017; 28 Jacobs (10.1016/j.bmc.2022.116748_b0510) 2011; 11 Kumar (10.1016/j.bmc.2022.116748_b0550) 2019; 63 Sanchorawala (10.1016/j.bmc.2022.116748_b0190) 2017; 130 10.1016/j.bmc.2022.116748_b0350 McDowell (10.1016/j.bmc.2022.116748_b0135) 2019; 35 Gronowitz (10.1016/j.bmc.2022.116748_b0275) 1971; 8 Nazarian (10.1016/j.bmc.2022.116748_b0145) 2009; 10 Liu (10.1016/j.bmc.2022.116748_b0115) 2020; 63 Wall (10.1016/j.bmc.2022.116748_b0710) 2018; 115 Das (10.1016/j.bmc.2022.116748_b0010) 2013; 5 Santos (10.1016/j.bmc.2022.116748_b0670) 2017; 138 Baker (10.1016/j.bmc.2022.116748_b0020) 2009; 1 Cunningham (10.1016/j.bmc.2022.116748_b0155) 2007; 16 Nocentini (10.1016/j.bmc.2022.116748_b0595) 2017; 8 Arrington (10.1016/j.bmc.2022.116748_b0645) 2018; 84 Cambray (10.1016/j.bmc.2022.116748_b0340) 2017; 53 Flint (10.1016/j.bmc.2022.116748_b0355) 2020; 15 Drawz (10.1016/j.bmc.2022.116748_b0100) 2010; 23 Davis (10.1016/j.bmc.2022.116748_b0345) 1998; 8 Baldwin (10.1016/j.bmc.2022.116748_b0470) 2018; 13 Akama (10.1016/j.bmc.2022.116748_b0750) 2019; 6 Johnson (10.1016/j.bmc.2022.116748_b0260) 2000; 11 Van Bocxlaer (10.1016/j.bmc.2022.116748_b0735) 2018; 62 Boghi (10.1016/j.bmc.2022.116748_b0380) 2018; 16 Kilic (10.1016/j.bmc.2022.116748_b0480) 2020; 917 Velasco (10.1016/j.bmc.2022.116748_b0405) 2007; 80 Mushtaq (10.1016/j.bmc.2022.116748_b0090) 2021; 76 Baldwin (10.1016/j.bmc.2022.116748_b0465) 2017; 24 Alley (10.1016/j.bmc.2022.116748_b0120) 2007; 16 Rubino (10.1016/j.bmc.2022.116748_b0235) 2018; 62 Patel (10.1016/j.bmc.2022.116748_b0565) 2017; 61 Hamrick (10.1016/j.bmc.2022.116748_b0110) 2020; 64 Ren (10.1016/j.bmc.2022.116748_b0675) 2020; 28 Golovanov (10.1016/j.bmc.2022.116748_b0045) 2021; 379 Purnapatre (10.1016/j.bmc.2022.116748_b0545) 2018; 62 Tevyashova (10.1016/j.bmc.2022.116748_b0040) 2021; 90 Song (10.1016/j.bmc.2022.116748_b0015) 2021; 11 Rosa (10.1016/j.bmc.2022.116748_b0475) 2020; 11 Zhang (10.1016/j.bmc.2022.116748_b0665) 2016; 26 Alam (10.1016/j.bmc.2022.116748_b0570) 2016; 72 Levy (10.1016/j.bmc.2022.116748_b0300) 2001; 309 Borys (10.1016/j.bmc.2022.116748_b0630) 2019; 1181 Suman (10.1016/j.bmc.2022.116748_b0660) 2015; 798 Gupta (10.1016/j.bmc.2022.116748_b0175) 2019; 58 Das (10.1016/j.bmc.2022.116748_b0050) 2022; 153657 Al-Zoubi (10.1016/j.bmc.2022.116748_b0530) 2017; 2017 Korkegian (10.1016/j.bmc.2022.116748_b0560) 2018; 108 Rombouts (10.1016/j.bmc.2022.116748_b0430) 2015; 58 Borys (10.1016/j.bmc.2022.116748_b0625) 2020; 10 Velasco-Bejarano (10.1016/j.bmc.2022.116748_b0410) 2007; 2007 O'Dwyer (10.1016/j.bmc.2022.116748_b0540) 2015; 59 Akama (10.1016/j.bmc.2022.116748_b0700) 2018; 28 Ward (10.1016/j.bmc.2022.116748_b0320) 2016; 24 Hu (10.1016/j.bmc.2022.116748_b0615) 2013; 3 Novelli (10.1016/j.bmc.2022.116748_b0030) 2020; 18 Zahid (10.1016/j.bmc.2022.116748_b0460) 2019; 10 Lapa (10.1016/j.bmc.2022.116748_b0585) 2017; 32 Markinson (10.1016/j.bmc.2022.116748_b0130) 2018; 108 Roujeinikova (10.1016/j.bmc.2022.116748_b0295) 1999; 274 Reece (10.1016/j.bmc.2022.116748_b0160) 2011; 67 Richardson (10.1016/j.bmc.2022.116748_b0180) 2014; 124 Moustafa (10.1016/j.bmc.2022.116748_b0140) 2014; 20 Raunio (10.1016/j.bmc.2022.116748_b0415) 2017; 7 Dong (10.1016/j.bmc.2022.116748_b0690) 2016; 358 10.1016/j.bmc.2022.116748_b0265 |
| References_xml | – volume: 108 start-page: 12 year: 2018 end-page: 19 ident: b0130 article-title: Examining the benefits of the boron-based mechanism of action and physicochemical properties of tavaborole in the treatment of onychomycosis publication-title: J Am Podiatr Med Assoc contributor: fullname: Winter – volume: 10 start-page: 4994 year: 2019 end-page: 4998 ident: b0445 article-title: Synthesis and characterization of an unnatural boron and nitrogen-containing tryptophan analogue and its incorporation into proteins publication-title: Chem Sci contributor: fullname: Li – volume: 53 start-page: 239 year: 2017 end-page: 245 ident: b0200 article-title: Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis publication-title: Drugs Today contributor: fullname: Paton – volume: 10 start-page: 1236 year: 2009 end-page: 1242 ident: b0145 article-title: AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis publication-title: Expert Opin Invest Drugs contributor: fullname: Weinberg – volume: 58 start-page: 3682 year: 2015 end-page: 3692 ident: b0095 article-title: Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases publication-title: J Med Chem contributor: fullname: Totrov – volume: 49 start-page: 4821 year: 2005 end-page: 4833 ident: b0525 article-title: Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents publication-title: Antimicrob Agents Chemother contributor: fullname: Chopra – volume: 28 start-page: 3676 year: 2018 end-page: 3680 ident: b0685 article-title: A hit deconstruction approach for the discovery of fetal hemoglobin inducers publication-title: Bioorganic Med Chem Lett contributor: fullname: Erickson-Miller – volume: 5 year: 2011 ident: b0255 article-title: SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis publication-title: PLoS Negl Trop Dis contributor: fullname: Wring – volume: 28 start-page: 493 year: 2018 end-page: 504 ident: b0490 article-title: Benzoxaborole compounds for therapeutic uses: a patent review (2010–2018) publication-title: Expert Opin Ther Pat contributor: fullname: Winum – volume: 90 start-page: 451 year: 2021 ident: b0040 article-title: Progress in the medical chemistry of organoboron compounds publication-title: Russ Chem Rev contributor: fullname: Chudinov – volume: 23 start-page: 2038 year: 2018 ident: b0555 article-title: Cinnamoyl-oxaborole amides: Synthesis and their in vitro biological activity publication-title: Molecules contributor: fullname: Mandizvo – volume: 68 start-page: 366 year: 2014 end-page: 372 ident: b0370 article-title: Synthesis, characterisation, and antifungal activities of novel benzodiazaborines publication-title: Aust J Chem contributor: fullname: Letourneau – volume: 26 start-page: 3182 year: 2016 end-page: 3186 ident: b0740 article-title: Optimization of isoxazoline amide benzoxaboroles for identification of a development candidate as an oral long acting animal ectoparasiticide, Bioorganic Med publication-title: Chem Lett contributor: fullname: Easom – volume: 59 start-page: 289 year: 2015 end-page: 298 ident: b0540 article-title: Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections publication-title: Antimicrob Agents Chemother contributor: fullname: Ingraham – volume: 124 start-page: 1038 year: 2014 end-page: 1046 ident: b0180 article-title: Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients publication-title: Blood, J Am Soc Hematol contributor: fullname: Wang – volume: 1 start-page: 1275 year: 2009 end-page: 1288 ident: b0020 article-title: Therapeutic potential of boron-containing compounds publication-title: Future Med Chem contributor: fullname: Akama – volume: 12 start-page: 431 year: 2011 end-page: 440 ident: b0165 article-title: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study publication-title: Lancet Oncol contributor: fullname: Grosicki – volume: 62 start-page: 6765 year: 2019 end-page: 6784 ident: b0650 article-title: Design, Synthesis, and Structure-Activity Relationship of 7-Propanamide Benzoxaboroles as Potent Anticancer Agents publication-title: J Med Chem contributor: fullname: Hao – volume: 23 start-page: 160 year: 2010 end-page: 201 ident: b0100 article-title: Three decades of β-lactamase inhibitors publication-title: Clin Microbiol Rev contributor: fullname: Bonomo – volume: 133 start-page: 152 year: 2017 end-page: 163 ident: b0580 article-title: Antibiotics in late clinical development publication-title: Biochem Pharmacol contributor: fullname: Martens – volume: 9 start-page: 201 year: 2018 end-page: 211 ident: b0755 article-title: Synthesis of biologically active boron-containing compounds publication-title: MedChemComm contributor: fullname: Zhang – volume: 57 start-page: 1394 year: 2013 end-page: 1403 ident: b0535 article-title: Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria publication-title: Antimicrob Agents Chemother contributor: fullname: Palencia – volume: 3 start-page: 1 year: 2013 end-page: 8 ident: b0615 article-title: Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase publication-title: Sci Rep contributor: fullname: Fang – volume: 1 start-page: 310 year: 2015 end-page: 316 ident: b0520 article-title: 4, 5-Disubstituted 6-aryloxy-1, 3-dihydrobenzo [c][1, 2] oxaboroles are Broad-Spectrum Serine β-Lactamase Inhibitors publication-title: ACS Infect Dis contributor: fullname: Eyermann – volume: 7 start-page: 20620 year: 2017 end-page: 20627 ident: b0415 article-title: Base catalysed N-functionalisation of boroxazolidones publication-title: RSC Adv contributor: fullname: Nguyen – volume: 63 start-page: 2789 year: 2020 end-page: 2801 ident: b0115 article-title: Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections publication-title: J Med Chem contributor: fullname: Chu – volume: 12 start-page: 358 year: 2017 ident: b0440 article-title: Medicinal chemistry profiling of monocyclic 1, 2-azaborines publication-title: ChemMedChem contributor: fullname: Karki – volume: 16 start-page: 1459 year: 2007 end-page: 1465 ident: b0155 article-title: Talabostat publication-title: Expert Opin Invest Drugs contributor: fullname: Cunningham – volume: 67 start-page: 57 year: 2011 end-page: 67 ident: b0160 article-title: Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma publication-title: Cancer Chemother Pharmacol contributor: fullname: Lonial – volume: 5 start-page: 653 year: 2013 end-page: 676 ident: b0010 article-title: Boron chemicals in diagnosis and therapeutics publication-title: Future Med Chem contributor: fullname: Karki – volume: 10 start-page: 2473 year: 2019 ident: b0395 article-title: Challenges and Limitations of Anti-quorum Sensing Therapies publication-title: Front Microbiol contributor: fullname: Krzyżek – volume: 80 start-page: 1007 year: 2007 end-page: 1013 ident: b0405 article-title: In vitro apoptotic activity of 2, 2-diphenyl-1, 3, 2-oxazaborolidin-5-ones in L5178Y cells publication-title: Life Sci contributor: fullname: Castillo – volume: 15 year: 2020 ident: b0355 article-title: InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis publication-title: PLoS ONE contributor: fullname: Parish – volume: 26 start-page: 3447 year: 2016 end-page: 3452 ident: b0485 article-title: Synthesis, characterization and antimicrobial activity of novel Schiff base tethered boronate esters of 1, 2-O-isopropylidene-α-d-xylofuranose publication-title: Bioorganic Med Chem. Lett contributor: fullname: Kumar – volume: 119 start-page: 8231 year: 2019 end-page: 8261 ident: b0005 article-title: Metallomimetic Chemistry of Boron publication-title: Chem Rev contributor: fullname: Braunschweig – volume: 28 year: 2020 ident: b0675 article-title: Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors publication-title: Bioorg Med Chem contributor: fullname: Zhao – volume: 52 start-page: 1181 year: 1996 end-page: 1184 ident: b0290 article-title: Crystallization of Escherichia coli enoyl reductase and its complex with diazaborine publication-title: Acta Crystallogr D Biol Crystallogr contributor: fullname: Sedelnikova – volume: 24 start-page: 6476 year: 2004 end-page: 6487 ident: b0360 article-title: Diazaborine treatment of yeast cells inhibits maturation of the 60S ribosomal subunit publication-title: Mol Cell Biol contributor: fullname: Schein – volume: 11 start-page: 3035 year: 2021 end-page: 3059 ident: b0015 article-title: Recent developments in the medicinal chemistry of single boron atom-containing compounds publication-title: Acta Pharmaceutica Sinica B contributor: fullname: Sun – volume: 27 start-page: 947 year: 1984 end-page: 953 ident: b0280 article-title: Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues publication-title: J Med Chem contributor: fullname: Hildebrandt – volume: 37 start-page: 35 year: 2019 end-page: 46 ident: b0655 article-title: Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology–phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells publication-title: Invest New Drugs contributor: fullname: Adamczyk-Woźniak – volume: 25 start-page: 1794 year: 2016 end-page: 1812 ident: b0375 article-title: Synthesis, characterization, antimicrobial activity, and QSAR studies on substituted oxadiazaboroles publication-title: Med Chem Res contributor: fullname: Budak – volume: 19 start-page: 2129 year: 2009 end-page: 2132 ident: b0500 article-title: Discovery and structure–activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis publication-title: Bioorganic Med Chem. Lett contributor: fullname: Zhang – volume: 274 start-page: 2107 year: 1996 end-page: 2110 ident: b0285 article-title: A mechanism of drug action revealed by structural studies of enoyl reductase publication-title: Science contributor: fullname: Sedelnikova – volume: 62 start-page: e02419 year: 2018 end-page: 02417 ident: b0735 article-title: Topical treatment for cutaneous leishmaniasis: dermato-pharmacokinetic lead optimization of benzoxaboroles publication-title: Antimicrob Agents Chemother contributor: fullname: Hauser – volume: 11 start-page: 1328 year: 2020 ident: b0475 article-title: Novel Alkyl (aryl)-Substituted 2, 2-Difluoro-6-(trichloromethyl)-2H-1, 3, 2-oxazaborinin-3-ium-2-uides: Synthesis, Antimicrobial Activity, and CT-DNA Binding Evaluations publication-title: Front Pharmacol contributor: fullname: Rodrigues – volume: 10 start-page: 217 year: 2016 ident: b0075 article-title: Spotlight on ixazomib: potential in the treatment of multiple myeloma publication-title: Drug Des. Devel contributor: fullname: Ou – volume: 62 start-page: e01987 year: 2018 end-page: 01917 ident: b0545 article-title: In vitro and in vivo activities of DS86760016, a novel leucyl-tRNA synthetase inhibitor for Gram-negative pathogens publication-title: Antimicrob Agents Chemother contributor: fullname: Pandya – volume: 23 start-page: 346 year: 2003 end-page: 368 ident: b0330 article-title: Boronic acid compounds as potential pharmaceutical agents publication-title: Med Res Rev contributor: fullname: Wang – volume: 64 start-page: e01963 year: 2020 end-page: 01919 ident: b0110 article-title: VNRX-5133 (taniborbactam), a broad-spectrum inhibitor of serine-and metallo-β-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa publication-title: Antimicrob Agents Chemother contributor: fullname: Uehara – volume: 26 start-page: 5797 year: 2016 end-page: 5801 ident: b0665 article-title: Chalcone–benzoxaborole hybrids as novel anticancer agents publication-title: Bioorganic Med Chem Lett contributor: fullname: Qiao – volume: 2007 start-page: 0921 year: 2007 end-page: 0924 ident: b0410 article-title: Preparation of apoptotic inducers, 2, 2-diphenyl-1, 3, 2-oxazaborolidin-5-ones, under alkaline conditions publication-title: Synlett contributor: fullname: Miranda – volume: 60 start-page: 4886 year: 2016 end-page: 4895 ident: b0730 article-title: Antimalarial benzoxaboroles target Plasmodium falciparum leucyl-tRNA synthetase publication-title: Antimicrob Agents Chemother contributor: fullname: Guo – volume: 32 start-page: 452 year: 2017 end-page: 456 ident: b0585 article-title: Two approaches to the use of benzo [c][1, 2] oxaboroles as active fragments for synthetic transformation of clarithromycin publication-title: J Enzyme Inhib Med Chem contributor: fullname: Isakova – volume: 53 start-page: 12532 year: 2017 end-page: 12535 ident: b0340 article-title: Fluorogenic diazaborine formation of semicarbazide with designed coumarin derivatives publication-title: ChemComm contributor: fullname: Gao – volume: 28 year: 2017 ident: b0760 article-title: Synthesis, characterization, antimicrobial activity, and QSAR studies of some new 6-substituted phenyl 3-(4-chlorophenyl)-3a, 4, 8, 8a-tetrahydro-[1, 3, 2] dioxaborepino [5, 6-d] isoxazoles publication-title: Heteroat Chem contributor: fullname: Budak – volume: 28 start-page: 493 year: 2018 end-page: 504 ident: b0035 article-title: Benzoxaborole compounds for therapeutic uses: a patent review (2010-2018) publication-title: Expert Opin Ther Pat contributor: fullname: Winum – volume: 35 start-page: 172 year: 2019 end-page: 178 ident: b0135 article-title: Crisaborole: a novel nonsteroidal topical treatment for atopic dermatitis publication-title: J Pharm Technol contributor: fullname: Olin – volume: 108 start-page: 96 year: 2018 end-page: 98 ident: b0560 article-title: The 7-phenyl benzoxaborole series is active against Mycobacterium tuberculosis publication-title: Tuberculosis contributor: fullname: Xia – volume: 153657 year: 2022 ident: b0050 article-title: Synthesis of a boron-containing amidoxime reagent and its application to synthesize functionalized oxadiazole and quinazolinone derivatives publication-title: Tetrahedron Lett contributor: fullname: Ojha – volume: 274 start-page: 30811 year: 1999 end-page: 30817 ident: b0295 article-title: Inhibitor binding studies on enoyl reductase reveal conformational changes related to substrate recognition publication-title: J Biol Chem contributor: fullname: de Boer – volume: 69 start-page: 549 year: 2016 end-page: 560 ident: b0635 article-title: New conjugates of polyene macrolide amphotericin B with benzoxaboroles: synthesis and properties publication-title: J. Antibiot. Res. contributor: fullname: Trenin – volume: 358 start-page: 413 year: 2016 end-page: 422 ident: b0690 article-title: Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors: selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes publication-title: J Pharmacol Exp Ther contributor: fullname: Zemska – volume: 10 start-page: 1205 year: 2019 end-page: 1210 ident: b0695 article-title: Bis-benzoxaboroles: Design, Synthesis, and Biological Evaluation as Carbonic Anhydrase Inhibitors publication-title: ACS Med Chem Lett contributor: fullname: Supuran – volume: 26 start-page: 491 year: 2005 end-page: 496 ident: b0390 article-title: Evaluation of oxazaborolidine activity on Streptococcus mutans biofilm formation publication-title: Int J Antimicrob Agents contributor: fullname: Zaks – volume: 58 start-page: 5445 year: 2015 end-page: 5458 ident: b0725 article-title: Click chemistry in lead optimization of boronic acids as β-lactamase inhibitors publication-title: J Med Chem contributor: fullname: Vahabi – volume: 10 start-page: 995 year: 2021 ident: b0085 article-title: Old and new beta-lactamase inhibitors: molecular structure, mechanism of action, and clinical use publication-title: Antibiotics contributor: fullname: Sulejmani – volume: 72 start-page: 3795 year: 2016 end-page: 3801 ident: b0570 article-title: Synthesis and evaluation of functionalized benzoboroxoles as potential anti-tuberculosis agents publication-title: Tetrahedron contributor: fullname: Gurrapu – volume: 60 start-page: 130 year: 2015 end-page: 135 ident: b0610 article-title: The influence of fluorine position on the properties of fluorobenzoxaboroles publication-title: Bioorg Chem contributor: fullname: Dominiak – volume: 1181 start-page: 587 year: 2019 end-page: 598 ident: b0630 article-title: Synthesis and structural elucidation of novel antifungal N-(fluorophenyl) piperazinyl benzoxaboroles and their analogues publication-title: J Mol Struct contributor: fullname: Wieczorek – volume: 84 start-page: 4680 year: 2018 end-page: 4694 ident: b0645 article-title: Convergent synthesis of the NS5B inhibitor GSK8175 enabled by transition metal catalysis publication-title: J Org Chem contributor: fullname: Calandra – volume: 57 start-page: 1902 year: 2014 end-page: 1913 ident: b0640 article-title: Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase publication-title: J Med Chem contributor: fullname: Ellis – volume: 62 start-page: e02228 year: 2018 end-page: 02217 ident: b0235 article-title: Phase 1 study of the safety, tolerability, and pharmacokinetics of vaborbactam and meropenem alone and in combination following single and multiple doses in healthy adult subjects publication-title: Antimicrob Agents Chemother contributor: fullname: Loutit – volume: 11 start-page: 455 year: 2000 end-page: 463 ident: b0260 article-title: Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus publication-title: Curr Opinion Investigational Drugs (London England) contributor: fullname: Johnson – volume: 24 start-page: 3267 year: 2016 end-page: 3275 ident: b0320 article-title: Identification of cellular targets of a series of boron heterocycles using TIPA II-A sensitive target identification platform publication-title: Bioorg Med Chem contributor: fullname: Martinez – volume: 63 start-page: 7491 year: 2020 end-page: 7507 ident: b0250 article-title: Discovery of cyclic boronic acid QPX7728, an ultrabroad-spectrum inhibitor of serine and metallo-β-lactamases publication-title: J Med Chem contributor: fullname: Lomovskaya – volume: 33 start-page: 286 year: 2018 end-page: 289 ident: b0605 article-title: Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles publication-title: J Enzyme Inhib Med Chem contributor: fullname: Winum – volume: 63 start-page: e02118 year: 2019 end-page: e02122 ident: b0550 article-title: DS86760016, a leucyl-tRNA synthetase inhibitor with activity against Pseudomonas aeruginosa publication-title: Antimicrob Agents Chemother contributor: fullname: Purnapatre – volume: 62 year: 2021 ident: b0450 article-title: Synthesis and biological evaluation of an antibacterial azaborine retinoid isostere publication-title: Tetrahedron Lett contributor: fullname: Wuest – volume: 917 year: 2020 ident: b0480 article-title: The synthesis of novel boronate esters and N-Heterocyclic carbene (NHC)-stabilized boronate esters: Spectroscopy, antimicrobial and antioxidant studies publication-title: J Organomet Chem contributor: fullname: Beyazsakal – volume: 60 start-page: 6326 year: 2016 end-page: 6332 ident: b0230 article-title: Phase 1 study of the safety, tolerability, and pharmacokinetics of the β-lactamase inhibitor vaborbactam (RPX7009) in healthy adult subjects publication-title: Antimicrob Agents Chemother contributor: fullname: Morgan – volume: 854 start-page: 194 year: 2019 end-page: 200 ident: b0420 article-title: In vitro anti-glioblastoma activity of L-valine derived boroxazolidones publication-title: Eur J Pharmacol contributor: fullname: Brown – volume: 11 start-page: 1301 year: 2011 ident: b0510 article-title: Molecule of the month publication-title: Curr Top Med Chem contributor: fullname: Don – volume: 61 start-page: e01205 year: 2017 end-page: e01217 ident: b0565 article-title: A novel 6-benzyl ether benzoxaborole is active against Mycobacterium tuberculosis in vitro publication-title: Antimicrob Agents Chemother contributor: fullname: Zhang – volume: 14 start-page: 659 year: 2007 end-page: 669 ident: b0425 article-title: Elemental isomerism: A boron-nitrogen surrogate for a carbon-carbon double bond increases the chemical diversity of estrogen receptor ligands publication-title: Chem Biol contributor: fullname: Bruning – volume: 8 start-page: 843 year: 1998 end-page: 846 ident: b0345 article-title: Syntheses and evaluation of benzodiazaborine compounds against M. tuberculosis H37Rv in vitro publication-title: Bioorganic Med Chem. Lett contributor: fullname: Martin – volume: 179 start-page: 791 year: 2019 end-page: 804 ident: b0025 article-title: Boron in drug design: Recent advances in the development of new therapeutic agents publication-title: Eur J Med Chem contributor: fullname: Dos Santos – volume: 17 start-page: 683 year: 2019 end-page: 691 ident: b0575 article-title: Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer publication-title: Org Biomol Chem contributor: fullname: Bai – volume: 8 start-page: 1 year: 2017 end-page: 11 ident: b0720 article-title: A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue publication-title: Nat Commun contributor: fullname: Lee – volume: 74 start-page: 1555 year: 2014 end-page: 1558 ident: b0210 article-title: Tavaborole: first global approval publication-title: Drugs contributor: fullname: Markham – volume: 47 start-page: 2409 year: 2004 end-page: 2410 ident: b0385 article-title: Synthesis and evaluation of oxazaborolidines for antibacterial activity against Streptococcus mutans publication-title: J Med Chem contributor: fullname: Dembitsky – volume: 16 start-page: 4849 year: 2018 end-page: 4856 ident: b0380 article-title: Valdecoxib vs. borazavaldecoxib: isoxazole BN/CC isosterism as a case study in designing and stabilizing boron heterocycles publication-title: Org Biomol Chem contributor: fullname: Hall – volume: 18 start-page: 643 year: 2020 end-page: 655 ident: b0030 article-title: Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination publication-title: Expert Rev Anti Infect Ther contributor: fullname: Rossolini – volume: 58 start-page: 431 year: 2019 end-page: 449 ident: b0175 article-title: Clinical pharmacology of ixazomib: The first oral proteasome inhibitor publication-title: Clin Pharmacokinet contributor: fullname: Xia – start-page: 2015 year: 2015 ident: b0080 article-title: Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling publication-title: Biomed Res Int contributor: fullname: Bolzoni – volume: 8 start-page: 377 year: 1971 end-page: 390 ident: b0275 article-title: Antibacterial borazaro derivatives. I. 5-Arylsulphonyl-4-hydroxy-4, 5-borazarothieno (2, 3-c) pyridines and 6-arylsulphonyl-7-hydroxy-7, 6-borazarothieno (3, 2-c) pyridines publication-title: Acta Pharm Suec contributor: fullname: Namtvedt – volume: 61 start-page: 3 year: 2016 end-page: 8 ident: b0590 article-title: Hybrid Antibiotics Based on Azithromycin and Glycopeptides: Synthesis and Antibacterial Activity publication-title: Antibiot Khimioter contributor: fullname: Isakova – volume: 93 start-page: 657 year: 2019 end-page: 665 ident: b0680 article-title: Design, synthesis and evaluations of spiro-fused benzoxaborin derivatives as novel boron-containing compounds publication-title: Chem Biol Drug Des contributor: fullname: Yamai – volume: 6 start-page: 173 year: 2019 end-page: 179 ident: b0750 article-title: Macrofilaricidal Benzimidazole-Benzoxaborole Hybrids as an Approach to the Treatment of River Blindness: Part 1. Amide Linked Analogs publication-title: ACS Infect. Dis contributor: fullname: Berry – volume: 130 start-page: 597 year: 2017 end-page: 605 ident: b0190 article-title: A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis publication-title: Blood, J Am Soc Hematol contributor: fullname: Kukreti – volume: 10 start-page: 2538 year: 2019 ident: b0460 article-title: Pharmacological inhibitors of the NLRP3 inflammasome publication-title: Front Immunol contributor: fullname: Kombe – volume: 102 start-page: 4639 year: 2002 end-page: 4750 ident: b0325 article-title: Irreversible inhibitors of serine, cysteine, and threonine proteases publication-title: Chem Rev contributor: fullname: Ekici – volume: 58 start-page: 9287 year: 2015 end-page: 9295 ident: b0430 article-title: Benzazaborinines as novel bioisosteric replacements of naphthalene: Propranolol as an example publication-title: J Med Chem contributor: fullname: Austin – volume: 138 start-page: 884 year: 2017 end-page: 889 ident: b0670 article-title: Antiproliferative and pro-apoptotic activities of 2′-and 4′-aminochalcones against tumor canine cells publication-title: Eur J Med Chem contributor: fullname: Garcia – volume: 28 start-page: 6 year: 2018 end-page: 10 ident: b0700 article-title: Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African Trypanosomiasis (AAT) publication-title: Bioorganic Med Chem Lett contributor: fullname: Freund – volume: 15 start-page: 1503 year: 2014 end-page: 1512 ident: b0185 article-title: Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study publication-title: Lancet Oncol contributor: fullname: Niesvizky – volume: 316 start-page: 1759 year: 2007 end-page: 1761 ident: b0620 article-title: An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site publication-title: Science contributor: fullname: Yaremchuk – volume: 96 start-page: 906 year: 2018 end-page: 911 ident: b0315 article-title: Synthesis, reactivity, and antimicrobial properties of boron-containing 4-ethyl-3-thiosemicarbazide derivatives publication-title: Can J Chem contributor: fullname: Stack – volume: 60 start-page: 5889 year: 2017 end-page: 5908 ident: b0715 article-title: Benzoxaborole antimalarial agents. Part 5. Lead optimization of novel amide pyrazinyloxy benzoxaboroles and identification of a preclinical candidate publication-title: J Med Chem contributor: fullname: Easom – volume: 8 start-page: 401 year: 2017 ident: b0060 article-title: Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma publication-title: J Adv Pract Oncol. contributor: fullname: Ramirez – volume: 586 start-page: 3410 year: 2012 end-page: 3414 ident: b0495 article-title: Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center publication-title: FEBS Lett contributor: fullname: Alley – volume: 115 start-page: 9616 year: 2018 end-page: 9621 ident: b0710 article-title: Clinical and veterinary trypanocidal benzoxaboroles target CPSF3 publication-title: Proc Natl Acad Sci contributor: fullname: Lukac – volume: 64 start-page: e00212 year: 2020 end-page: e220 ident: b0105 article-title: Spectrum of beta-lactamase inhibition by the cyclic boronate QPX7728, an ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases: enhancement of activity of multiple antibiotics against isogenic strains expressing single beta-lactamases publication-title: Antimicrob Agents Chemother contributor: fullname: Nelson – volume: 23 start-page: 479 year: 2009 end-page: 486 ident: b0150 article-title: Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4) publication-title: Best Pract Res Clin Endocrinol Metab contributor: fullname: Gallwitz – volume: 11 start-page: 2277 year: 2020 end-page: 2284 ident: b0515 article-title: Benzoxaboroles: new potent inhibitors of the carbonic anhydrases of the pathogenic bacterium Vibrio cholerae publication-title: ACS Med Chem Lett contributor: fullname: Cadoni – volume: 379 start-page: 8 year: 2021 ident: b0045 article-title: Merging Boron with Nitrogen-Oxygen Bonds: A Review on BON publication-title: Heterocycles contributor: fullname: Sukhorukov – volume: 9 start-page: 6316 year: 2003 end-page: 6325 ident: b0065 article-title: The proteasome as a target for cancer therapy publication-title: Clin Cancer Res contributor: fullname: O’Neil – volume: 76 start-page: 160 year: 2021 end-page: 170 ident: b0090 article-title: Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria publication-title: J Antimicrob Chemother contributor: fullname: Livermore – volume: 65 year: 2021 ident: b0240 article-title: Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor publication-title: Antimicrob Agents Chemother contributor: fullname: Henkel – volume: 71 start-page: 1521 year: 2015 end-page: 1530 ident: b0310 article-title: Crystallographic insights into the structure-activity relationships of diazaborine enoyl-ACP reductase inhibitors publication-title: Acta Crystallogr F Struct Biol Commun contributor: fullname: Serobyan – volume: 52 start-page: 11983 year: 2016 end-page: 11986 ident: b0600 article-title: Benzoxaborole as a new chemotype for carbonic anhydrase inhibition publication-title: ChemComm. contributor: fullname: Esposito – volume: 24 start-page: 1321 year: 2017 end-page: 1335 ident: b0465 article-title: Boron-based inhibitors of the NLRP3 inflammasome publication-title: Cell Chem. Biol. contributor: fullname: Daniels – volume: 13 start-page: 312 year: 2018 ident: b0470 article-title: Design, synthesis and evaluation of oxazaborine inhibitors of the NLRP3 inflammasome publication-title: ChemMedChem contributor: fullname: Swanton – volume: 10 start-page: 37187 year: 2020 end-page: 37193 ident: b0625 article-title: Mechanochemical synthesis of antifungal bis (benzoxaboroles) publication-title: RSC Adv contributor: fullname: Tarkowska – volume: 21 start-page: 838 year: 2007 end-page: 842 ident: b0070 article-title: Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma publication-title: Leukemia contributor: fullname: Basso – volume: 2017 start-page: 5800 year: 2017 end-page: 5808 ident: b0530 article-title: Design, Synthesis and X-ray Crystal Structure of Iodinated Benzoboroxole Derivatives by Consecutive Metal-Iodine Exchange of 3, 4, 5-Triiodoanisole publication-title: Eur J Org Chem contributor: fullname: Jaradat – volume: 21 start-page: 660 year: 2013 end-page: 667 ident: b0765 article-title: Synthesis and evaluation of thiazolidinedione and dioxazaborocane analogues as inhibitors of AI-2 quorum sensing in Vibrio harveyi publication-title: Bioorg Med Chem contributor: fullname: Enk – volume: 81 start-page: 59 year: 2014 end-page: 75 ident: b0745 article-title: Novel pyrrolobenzoxaboroles: Design, synthesis, and biological evaluation against Trypanosoma brucei publication-title: Eur J Med Chem contributor: fullname: Meng – volume: 309 start-page: 171 year: 2001 end-page: 180 ident: b0300 article-title: A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase publication-title: J Mol Biol contributor: fullname: Wallace – volume: 23 start-page: 4453 year: 2015 end-page: 4461 ident: b0435 article-title: BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors publication-title: Bioorg Med Chem contributor: fullname: Kilburn – volume: 14 start-page: 1007 year: 2018 end-page: 1021 ident: b0225 article-title: Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection publication-title: Expert Opin Drug Metab Toxicol contributor: fullname: Rodvold – volume: 3 start-page: 7418 year: 2018 end-page: 7423 ident: b0335 article-title: Diazaborines as new inhibitors of human neutrophil elastase publication-title: ACS Omega contributor: fullname: Guedes – volume: 16 start-page: 1596 year: 2008 end-page: 1604 ident: b0400 article-title: Oxazaborolidine derivatives inducing autoinducer-2 signal transduction in Vibrio harveyi publication-title: Bioorg Med Chem contributor: fullname: Jabbour – volume: 60 start-page: 8011 year: 2017 end-page: 8026 ident: b0245 article-title: Discovery of a potent and specific M. tuberculosis Leucyl-tRNA synthetase inhibitor:(S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy) benzo [c][1, 2] oxaborol-1 (3 H)-ol (GSK656) publication-title: J Medicinal Chem contributor: fullname: Rock – volume: 8 start-page: 1194 year: 2017 end-page: 1198 ident: b0595 article-title: Benzoxaboroles as efficient inhibitors of the β-carbonic anhydrases from pathogenic fungi: activity and modeling study publication-title: ACS Med Chem Lett contributor: fullname: Del Prete – volume: 102 start-page: 909 year: 2010 end-page: 912 ident: b0270 article-title: Pediatric phase I trial design using maximum target inhibition as the primary endpoint publication-title: J Natl Cancer Inst contributor: fullname: Aikin – volume: 10 start-page: 361 year: 2003 end-page: 369 ident: b0505 article-title: Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers publication-title: Cancer control contributor: fullname: Anderson – volume: 5 start-page: 2415 year: 2008 end-page: 2422 ident: b0365 article-title: Synthesis, characterization, and antifungal activity of boron-containing thiosemicarbazones publication-title: Chem Biodivers contributor: fullname: Vogels – volume: 798 start-page: 125 year: 2015 end-page: 131 ident: b0660 article-title: Synthesis and evaluation of functionalized aminobenzoboroxoles as potential anti-cancer agents publication-title: J Organomet Chem contributor: fullname: Kasibotla – volume: 12 year: 2018 ident: b0705 article-title: Benzoxaborole treatment perturbs S-adenosyl-L-methionine metabolism in Trypanosoma brucei publication-title: PLoS Negl Trop Dis contributor: fullname: Achcar – volume: 11 start-page: 1381 year: 2014 end-page: 1397 ident: b0305 article-title: Synthesis, characterization, and antibacterial activity of structurally complex 2-acylated 2,3,1-benzodiazaborines and related compounds publication-title: Chem Biodivers contributor: fullname: Kosmowska – volume: 16 start-page: 157 year: 2007 end-page: 167 ident: b0120 article-title: Recent progress on the topical therapy of onychomycosis publication-title: Expert Opin Invest Drugs contributor: fullname: Beutner – volume: 10 start-page: 1 year: 2019 end-page: 11 ident: b0455 article-title: Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors publication-title: Cell Death Dis contributor: fullname: Kouadir – volume: 15 start-page: 1439 year: 2014 end-page: 1448 ident: b0215 article-title: Tavaborole for the treatment of onychomycosis publication-title: Expert Opin Pharmacother contributor: fullname: Tosti – year: 2007 ident: b0125 article-title: An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site publication-title: Science contributor: fullname: Yaremchuk – volume: 20 year: 2014 ident: b0140 article-title: A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology publication-title: Dermatol Online J contributor: fullname: Feldman – volume: 24 start-page: 3267 year: 2016 ident: 10.1016/j.bmc.2022.116748_b0320 article-title: Identification of cellular targets of a series of boron heterocycles using TIPA II-A sensitive target identification platform publication-title: Bioorg Med Chem doi: 10.1016/j.bmc.2016.05.058 contributor: fullname: Ward – volume: 61 start-page: e01205 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0565 article-title: A novel 6-benzyl ether benzoxaborole is active against Mycobacterium tuberculosis in vitro publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01205-17 contributor: fullname: Patel – volume: 10 start-page: 361 year: 2003 ident: 10.1016/j.bmc.2022.116748_b0505 article-title: Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers publication-title: Cancer control doi: 10.1177/107327480301000502 contributor: fullname: Richardson – volume: 11 start-page: 1381 year: 2014 ident: 10.1016/j.bmc.2022.116748_b0305 article-title: Synthesis, characterization, and antibacterial activity of structurally complex 2-acylated 2,3,1-benzodiazaborines and related compounds publication-title: Chem Biodivers doi: 10.1002/cbdv.201400007 contributor: fullname: Kanichar – volume: 1 start-page: 1275 year: 2009 ident: 10.1016/j.bmc.2022.116748_b0020 article-title: Therapeutic potential of boron-containing compounds publication-title: Future Med Chem doi: 10.4155/fmc.09.71 contributor: fullname: Baker – volume: 11 start-page: 455 issue: 2010 year: 2000 ident: 10.1016/j.bmc.2022.116748_b0260 article-title: Dutogliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus publication-title: Curr Opinion Investigational Drugs (London England) contributor: fullname: Johnson – volume: 26 start-page: 3182 year: 2016 ident: 10.1016/j.bmc.2022.116748_b0740 article-title: Optimization of isoxazoline amide benzoxaboroles for identification of a development candidate as an oral long acting animal ectoparasiticide, Bioorganic Med publication-title: Chem Lett doi: 10.1016/j.bmcl.2016.04.093 contributor: fullname: Zhang – volume: 47 start-page: 2409 year: 2004 ident: 10.1016/j.bmc.2022.116748_b0385 article-title: Synthesis and evaluation of oxazaborolidines for antibacterial activity against Streptococcus mutans publication-title: J Med Chem doi: 10.1021/jm049899b contributor: fullname: Jabbour – volume: 28 year: 2020 ident: 10.1016/j.bmc.2022.116748_b0675 article-title: Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors publication-title: Bioorg Med Chem doi: 10.1016/j.bmc.2019.115236 contributor: fullname: Ren – volume: 5 year: 2011 ident: 10.1016/j.bmc.2022.116748_b0255 article-title: SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0001151 contributor: fullname: Jacobs – volume: 62 year: 2021 ident: 10.1016/j.bmc.2022.116748_b0450 article-title: Synthesis and biological evaluation of an antibacterial azaborine retinoid isostere publication-title: Tetrahedron Lett doi: 10.1016/j.tetlet.2020.152667 contributor: fullname: Haney – volume: 63 start-page: 2789 year: 2020 ident: 10.1016/j.bmc.2022.116748_b0115 article-title: Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections publication-title: J Med Chem doi: 10.1021/acs.jmedchem.9b01518 contributor: fullname: Liu – volume: 58 start-page: 431 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0175 article-title: Clinical pharmacology of ixazomib: The first oral proteasome inhibitor publication-title: Clin Pharmacokinet doi: 10.1007/s40262-018-0702-1 contributor: fullname: Gupta – volume: 16 start-page: 4849 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0380 article-title: Valdecoxib vs. borazavaldecoxib: isoxazole BN/CC isosterism as a case study in designing and stabilizing boron heterocycles publication-title: Org Biomol Chem doi: 10.1039/C8OB00998H contributor: fullname: Boghi – volume: 358 start-page: 413 year: 2016 ident: 10.1016/j.bmc.2022.116748_b0690 article-title: Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors: selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.116.232819 contributor: fullname: Dong – volume: 16 start-page: 1459 year: 2007 ident: 10.1016/j.bmc.2022.116748_b0155 article-title: Talabostat publication-title: Expert Opin Invest Drugs doi: 10.1517/13543784.16.9.1459 contributor: fullname: Cunningham – volume: 14 start-page: 1007 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0225 article-title: Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection publication-title: Expert Opin Drug Metab Toxicol doi: 10.1080/17425255.2018.1511702 contributor: fullname: Burgos – volume: 26 start-page: 5797 year: 2016 ident: 10.1016/j.bmc.2022.116748_b0665 article-title: Chalcone–benzoxaborole hybrids as novel anticancer agents publication-title: Bioorganic Med Chem Lett doi: 10.1016/j.bmcl.2016.10.024 contributor: fullname: Zhang – volume: 10 start-page: 37187 year: 2020 ident: 10.1016/j.bmc.2022.116748_b0625 article-title: Mechanochemical synthesis of antifungal bis (benzoxaboroles) publication-title: RSC Adv doi: 10.1039/D0RA07767D contributor: fullname: Borys – volume: 64 start-page: e00212 year: 2020 ident: 10.1016/j.bmc.2022.116748_b0105 publication-title: Antimicrob Agents Chemother contributor: fullname: Lomovskaya – volume: 10 start-page: 4994 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0445 article-title: Synthesis and characterization of an unnatural boron and nitrogen-containing tryptophan analogue and its incorporation into proteins publication-title: Chem Sci doi: 10.1039/C8SC05167D contributor: fullname: Boknevitz – volume: 8 start-page: 843 year: 1998 ident: 10.1016/j.bmc.2022.116748_b0345 article-title: Syntheses and evaluation of benzodiazaborine compounds against M. tuberculosis H37Rv in vitro publication-title: Bioorganic Med Chem. Lett doi: 10.1016/S0960-894X(98)00126-7 contributor: fullname: Davis – volume: 23 start-page: 346 year: 2003 ident: 10.1016/j.bmc.2022.116748_b0330 article-title: Boronic acid compounds as potential pharmaceutical agents publication-title: Med Res Rev doi: 10.1002/med.10043 contributor: fullname: Yang – volume: 10 start-page: 1236 year: 2009 ident: 10.1016/j.bmc.2022.116748_b0145 article-title: AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis publication-title: Expert Opin Invest Drugs contributor: fullname: Nazarian – volume: 2017 start-page: 5800 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0530 article-title: Design, Synthesis and X-ray Crystal Structure of Iodinated Benzoboroxole Derivatives by Consecutive Metal-Iodine Exchange of 3, 4, 5-Triiodoanisole publication-title: Eur J Org Chem doi: 10.1002/ejoc.201700989 contributor: fullname: Al-Zoubi – volume: 19 start-page: 2129 year: 2009 ident: 10.1016/j.bmc.2022.116748_b0500 article-title: Discovery and structure–activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis publication-title: Bioorganic Med Chem. Lett doi: 10.1016/j.bmcl.2009.03.007 contributor: fullname: Akama – volume: 8 start-page: 1194 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0595 article-title: Benzoxaboroles as efficient inhibitors of the β-carbonic anhydrases from pathogenic fungi: activity and modeling study publication-title: ACS Med Chem Lett doi: 10.1021/acsmedchemlett.7b00369 contributor: fullname: Nocentini – volume: 130 start-page: 597 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0190 article-title: A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis publication-title: Blood, J Am Soc Hematol contributor: fullname: Sanchorawala – volume: 68 start-page: 366 year: 2014 ident: 10.1016/j.bmc.2022.116748_b0370 article-title: Synthesis, characterisation, and antifungal activities of novel benzodiazaborines publication-title: Aust J Chem doi: 10.1071/CH14534 contributor: fullname: Yang – volume: 63 start-page: 7491 year: 2020 ident: 10.1016/j.bmc.2022.116748_b0250 article-title: Discovery of cyclic boronic acid QPX7728, an ultrabroad-spectrum inhibitor of serine and metallo-β-lactamases publication-title: J Med Chem doi: 10.1021/acs.jmedchem.9b01976 contributor: fullname: Hecker – volume: 33 start-page: 286 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0605 article-title: Carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani chagasi are inhibited by benzoxaboroles publication-title: J Enzyme Inhib Med Chem doi: 10.1080/14756366.2017.1414808 contributor: fullname: Nocentini – ident: 10.1016/j.bmc.2022.116748_b0205 – volume: 11 start-page: 2277 year: 2020 ident: 10.1016/j.bmc.2022.116748_b0515 article-title: Benzoxaboroles: new potent inhibitors of the carbonic anhydrases of the pathogenic bacterium Vibrio cholerae publication-title: ACS Med Chem Lett doi: 10.1021/acsmedchemlett.0c00403 contributor: fullname: Bonardi – volume: 60 start-page: 130 year: 2015 ident: 10.1016/j.bmc.2022.116748_b0610 article-title: The influence of fluorine position on the properties of fluorobenzoxaboroles publication-title: Bioorg Chem doi: 10.1016/j.bioorg.2015.05.004 contributor: fullname: Adamczyk-Woźniak – volume: 12 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0705 article-title: Benzoxaborole treatment perturbs S-adenosyl-L-methionine metabolism in Trypanosoma brucei publication-title: PLoS Negl Trop Dis doi: 10.1371/journal.pntd.0006450 contributor: fullname: Steketee – volume: 9 start-page: 6316 year: 2003 ident: 10.1016/j.bmc.2022.116748_b0065 article-title: The proteasome as a target for cancer therapy publication-title: Clin Cancer Res contributor: fullname: Voorhees – volume: 65 year: 2021 ident: 10.1016/j.bmc.2022.116748_b0240 article-title: Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous β-Lactamase Inhibitor publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01053-21 contributor: fullname: Dowell – ident: 10.1016/j.bmc.2022.116748_b0350 doi: 10.26508/lsa.201800025 – volume: 93 start-page: 657 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0680 article-title: Design, synthesis and evaluations of spiro-fused benzoxaborin derivatives as novel boron-containing compounds publication-title: Chem Biol Drug Des doi: 10.1111/cbdd.13496 contributor: fullname: Natsutani – volume: 1181 start-page: 587 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0630 article-title: Synthesis and structural elucidation of novel antifungal N-(fluorophenyl) piperazinyl benzoxaboroles and their analogues publication-title: J Mol Struct doi: 10.1016/j.molstruc.2019.01.018 contributor: fullname: Borys – volume: 3 start-page: 7418 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0335 article-title: Diazaborines as new inhibitors of human neutrophil elastase publication-title: ACS Omega doi: 10.1021/acsomega.8b00702 contributor: fullname: António – volume: 586 start-page: 3410 year: 2012 ident: 10.1016/j.bmc.2022.116748_b0495 article-title: Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center publication-title: FEBS Lett doi: 10.1016/j.febslet.2012.07.058 contributor: fullname: Freund – volume: 13 start-page: 312 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0470 article-title: Design, synthesis and evaluation of oxazaborine inhibitors of the NLRP3 inflammasome publication-title: ChemMedChem doi: 10.1002/cmdc.201700731 contributor: fullname: Baldwin – volume: 11 start-page: 1301 year: 2011 ident: 10.1016/j.bmc.2022.116748_b0510 article-title: Molecule of the month publication-title: Curr Top Med Chem doi: 10.2174/1568026611107011301 contributor: fullname: Jacobs – volume: 5 start-page: 2415 year: 2008 ident: 10.1016/j.bmc.2022.116748_b0365 article-title: Synthesis, characterization, and antifungal activity of boron-containing thiosemicarbazones publication-title: Chem Biodivers doi: 10.1002/cbdv.200890206 contributor: fullname: Hicks – volume: 10 start-page: 995 year: 2021 ident: 10.1016/j.bmc.2022.116748_b0085 article-title: Old and new beta-lactamase inhibitors: molecular structure, mechanism of action, and clinical use publication-title: Antibiotics doi: 10.3390/antibiotics10080995 contributor: fullname: Carcione – volume: 179 start-page: 791 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0025 article-title: Boron in drug design: Recent advances in the development of new therapeutic agents publication-title: Eur J Med Chem doi: 10.1016/j.ejmech.2019.06.092 contributor: fullname: Fernandes – volume: 58 start-page: 9287 year: 2015 ident: 10.1016/j.bmc.2022.116748_b0430 article-title: Benzazaborinines as novel bioisosteric replacements of naphthalene: Propranolol as an example publication-title: J Med Chem doi: 10.1021/acs.jmedchem.5b01088 contributor: fullname: Rombouts – volume: 9 start-page: 201 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0755 article-title: Synthesis of biologically active boron-containing compounds publication-title: MedChemComm doi: 10.1039/C7MD00552K contributor: fullname: Yang – volume: 26 start-page: 3447 year: 2016 ident: 10.1016/j.bmc.2022.116748_b0485 article-title: Synthesis, characterization and antimicrobial activity of novel Schiff base tethered boronate esters of 1, 2-O-isopropylidene-α-d-xylofuranose publication-title: Bioorganic Med Chem. Lett doi: 10.1016/j.bmcl.2016.06.049 contributor: fullname: Reddy – volume: 62 start-page: 6765 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0650 article-title: Design, Synthesis, and Structure-Activity Relationship of 7-Propanamide Benzoxaboroles as Potent Anticancer Agents publication-title: J Med Chem doi: 10.1021/acs.jmedchem.9b00736 contributor: fullname: Zhang – volume: 15 start-page: 1439 year: 2014 ident: 10.1016/j.bmc.2022.116748_b0215 article-title: Tavaborole for the treatment of onychomycosis publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.2014.921158 contributor: fullname: Elewski – volume: 133 start-page: 152 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0580 article-title: Antibiotics in late clinical development publication-title: Biochem Pharmacol doi: 10.1016/j.bcp.2016.09.025 contributor: fullname: Fernandes – volume: 60 start-page: 8011 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0245 article-title: Discovery of a potent and specific M. tuberculosis Leucyl-tRNA synthetase inhibitor:(S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy) benzo [c][1, 2] oxaborol-1 (3 H)-ol (GSK656) publication-title: J Medicinal Chem doi: 10.1021/acs.jmedchem.7b00631 contributor: fullname: Li – volume: 28 start-page: 493 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0035 article-title: Benzoxaborole compounds for therapeutic uses: a patent review (2010-2018) publication-title: Expert Opin Ther Pat doi: 10.1080/13543776.2018.1473379 contributor: fullname: Nocentini – volume: 12 start-page: 358 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0440 article-title: Medicinal chemistry profiling of monocyclic 1, 2-azaborines publication-title: ChemMedChem doi: 10.1002/cmdc.201700047 contributor: fullname: Zhao – volume: 74 start-page: 1555 year: 2014 ident: 10.1016/j.bmc.2022.116748_b0210 article-title: Tavaborole: first global approval publication-title: Drugs doi: 10.1007/s40265-014-0276-7 contributor: fullname: Markham – volume: 917 year: 2020 ident: 10.1016/j.bmc.2022.116748_b0480 article-title: The synthesis of novel boronate esters and N-Heterocyclic carbene (NHC)-stabilized boronate esters: Spectroscopy, antimicrobial and antioxidant studies publication-title: J Organomet Chem doi: 10.1016/j.jorganchem.2020.121268 contributor: fullname: Kilic – volume: 28 start-page: 6 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0700 article-title: Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African Trypanosomiasis (AAT) publication-title: Bioorganic Med Chem Lett doi: 10.1016/j.bmcl.2017.11.028 contributor: fullname: Akama – ident: 10.1016/j.bmc.2022.116748_b0220 – volume: 69 start-page: 549 year: 2016 ident: 10.1016/j.bmc.2022.116748_b0635 article-title: New conjugates of polyene macrolide amphotericin B with benzoxaboroles: synthesis and properties publication-title: J. Antibiot. Res. doi: 10.1038/ja.2016.34 contributor: fullname: Tevyashova – volume: 28 start-page: 493 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0490 article-title: Benzoxaborole compounds for therapeutic uses: a patent review (2010–2018) publication-title: Expert Opin Ther Pat doi: 10.1080/13543776.2018.1473379 contributor: fullname: Nocentini – volume: 62 start-page: e01987 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0545 article-title: In vitro and in vivo activities of DS86760016, a novel leucyl-tRNA synthetase inhibitor for Gram-negative pathogens publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01987-17 contributor: fullname: Purnapatre – volume: 23 start-page: 160 year: 2010 ident: 10.1016/j.bmc.2022.116748_b0100 article-title: Three decades of β-lactamase inhibitors publication-title: Clin Microbiol Rev doi: 10.1128/CMR.00037-09 contributor: fullname: Drawz – volume: 138 start-page: 884 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0670 article-title: Antiproliferative and pro-apoptotic activities of 2′-and 4′-aminochalcones against tumor canine cells publication-title: Eur J Med Chem doi: 10.1016/j.ejmech.2017.06.049 contributor: fullname: Santos – volume: 52 start-page: 1181 year: 1996 ident: 10.1016/j.bmc.2022.116748_b0290 article-title: Crystallization of Escherichia coli enoyl reductase and its complex with diazaborine publication-title: Acta Crystallogr D Biol Crystallogr doi: 10.1107/S0907444996005458 contributor: fullname: Baldock – volume: 60 start-page: 5889 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0715 article-title: Benzoxaborole antimalarial agents. Part 5. Lead optimization of novel amide pyrazinyloxy benzoxaboroles and identification of a preclinical candidate publication-title: J Med Chem doi: 10.1021/acs.jmedchem.7b00621 contributor: fullname: Zhang – volume: 102 start-page: 909 year: 2010 ident: 10.1016/j.bmc.2022.116748_b0270 article-title: Pediatric phase I trial design using maximum target inhibition as the primary endpoint publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djq174 contributor: fullname: Meany – volume: 5 start-page: 653 year: 2013 ident: 10.1016/j.bmc.2022.116748_b0010 article-title: Boron chemicals in diagnosis and therapeutics publication-title: Future Med Chem doi: 10.4155/fmc.13.38 contributor: fullname: Das – volume: 18 start-page: 643 year: 2020 ident: 10.1016/j.bmc.2022.116748_b0030 article-title: Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination publication-title: Expert Rev Anti Infect Ther doi: 10.1080/14787210.2020.1756775 contributor: fullname: Novelli – year: 2007 ident: 10.1016/j.bmc.2022.116748_b0125 article-title: An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site publication-title: Science doi: 10.1126/science.1142189 contributor: fullname: Rock – volume: 27 start-page: 947 year: 1984 ident: 10.1016/j.bmc.2022.116748_b0280 article-title: Preparation and antibacterial activities of new 1,2,3-diazaborine derivatives and analogues publication-title: J Med Chem doi: 10.1021/jm00374a003 contributor: fullname: Grassberger – volume: 60 start-page: 6326 year: 2016 ident: 10.1016/j.bmc.2022.116748_b0230 article-title: Phase 1 study of the safety, tolerability, and pharmacokinetics of the β-lactamase inhibitor vaborbactam (RPX7009) in healthy adult subjects publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00568-16 contributor: fullname: Griffith – volume: 49 start-page: 4821 year: 2005 ident: 10.1016/j.bmc.2022.116748_b0525 article-title: Prospects for aminoacyl-tRNA synthetase inhibitors as new antimicrobial agents publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.49.12.4821-4833.2005 contributor: fullname: Hurdle – volume: 72 start-page: 3795 year: 2016 ident: 10.1016/j.bmc.2022.116748_b0570 article-title: Synthesis and evaluation of functionalized benzoboroxoles as potential anti-tuberculosis agents publication-title: Tetrahedron doi: 10.1016/j.tet.2016.03.038 contributor: fullname: Alam – volume: 11 start-page: 1328 year: 2020 ident: 10.1016/j.bmc.2022.116748_b0475 article-title: Novel Alkyl (aryl)-Substituted 2, 2-Difluoro-6-(trichloromethyl)-2H-1, 3, 2-oxazaborinin-3-ium-2-uides: Synthesis, Antimicrobial Activity, and CT-DNA Binding Evaluations publication-title: Front Pharmacol doi: 10.3389/fphar.2020.01328 contributor: fullname: Rosa – volume: 62 start-page: e02228 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0235 article-title: Phase 1 study of the safety, tolerability, and pharmacokinetics of vaborbactam and meropenem alone and in combination following single and multiple doses in healthy adult subjects publication-title: Antimicrob Agents Chemother contributor: fullname: Rubino – volume: 309 start-page: 171 year: 2001 ident: 10.1016/j.bmc.2022.116748_b0300 article-title: A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase publication-title: J Mol Biol doi: 10.1006/jmbi.2001.4643 contributor: fullname: Levy – volume: 16 start-page: 1596 year: 2008 ident: 10.1016/j.bmc.2022.116748_b0400 article-title: Oxazaborolidine derivatives inducing autoinducer-2 signal transduction in Vibrio harveyi publication-title: Bioorg Med Chem doi: 10.1016/j.bmc.2007.11.032 contributor: fullname: Aharoni – volume: 52 start-page: 11983 year: 2016 ident: 10.1016/j.bmc.2022.116748_b0600 article-title: Benzoxaborole as a new chemotype for carbonic anhydrase inhibition publication-title: ChemComm. contributor: fullname: Alterio – volume: 24 start-page: 6476 year: 2004 ident: 10.1016/j.bmc.2022.116748_b0360 article-title: Diazaborine treatment of yeast cells inhibits maturation of the 60S ribosomal subunit publication-title: Mol Cell Biol doi: 10.1128/MCB.24.14.6476-6487.2004 contributor: fullname: Pertschy – volume: 61 start-page: 3 year: 2016 ident: 10.1016/j.bmc.2022.116748_b0590 article-title: Hybrid Antibiotics Based on Azithromycin and Glycopeptides: Synthesis and Antibacterial Activity publication-title: Antibiot Khimioter contributor: fullname: Printsevskaya – volume: 24 start-page: 1321 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0465 article-title: Boron-based inhibitors of the NLRP3 inflammasome publication-title: Cell Chem. Biol. doi: 10.1016/j.chembiol.2017.08.011 contributor: fullname: Baldwin – volume: 96 start-page: 906 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0315 article-title: Synthesis, reactivity, and antimicrobial properties of boron-containing 4-ethyl-3-thiosemicarbazide derivatives publication-title: Can J Chem doi: 10.1139/cjc-2018-0108 contributor: fullname: Scott – volume: 67 start-page: 57 year: 2011 ident: 10.1016/j.bmc.2022.116748_b0160 article-title: Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma publication-title: Cancer Chemother Pharmacol doi: 10.1007/s00280-010-1283-3 contributor: fullname: Reece – volume: 15 year: 2020 ident: 10.1016/j.bmc.2022.116748_b0355 article-title: InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis publication-title: PLoS ONE doi: 10.1371/journal.pone.0239354 contributor: fullname: Flint – volume: 119 start-page: 8231 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0005 article-title: Metallomimetic Chemistry of Boron publication-title: Chem Rev doi: 10.1021/acs.chemrev.8b00561 contributor: fullname: Légaré – volume: 26 start-page: 491 year: 2005 ident: 10.1016/j.bmc.2022.116748_b0390 article-title: Evaluation of oxazaborolidine activity on Streptococcus mutans biofilm formation publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2005.08.018 contributor: fullname: Jabbour – volume: 58 start-page: 3682 year: 2015 ident: 10.1016/j.bmc.2022.116748_b0095 article-title: Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases publication-title: J Med Chem doi: 10.1021/acs.jmedchem.5b00127 contributor: fullname: Hecker – volume: 11 start-page: 3035 year: 2021 ident: 10.1016/j.bmc.2022.116748_b0015 article-title: Recent developments in the medicinal chemistry of single boron atom-containing compounds publication-title: Acta Pharmaceutica Sinica B doi: 10.1016/j.apsb.2021.01.010 contributor: fullname: Song – ident: 10.1016/j.bmc.2022.116748_b0055 – volume: 23 start-page: 4453 year: 2015 ident: 10.1016/j.bmc.2022.116748_b0435 article-title: BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors publication-title: Bioorg Med Chem doi: 10.1016/j.bmc.2015.06.019 contributor: fullname: Vlasceanu – volume: 60 start-page: 4886 year: 2016 ident: 10.1016/j.bmc.2022.116748_b0730 article-title: Antimalarial benzoxaboroles target Plasmodium falciparum leucyl-tRNA synthetase publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00820-16 contributor: fullname: Sonoiki – volume: 153657 year: 2022 ident: 10.1016/j.bmc.2022.116748_b0050 article-title: Synthesis of a boron-containing amidoxime reagent and its application to synthesize functionalized oxadiazole and quinazolinone derivatives publication-title: Tetrahedron Lett contributor: fullname: Das – volume: 63 start-page: e02118 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0550 article-title: DS86760016, a leucyl-tRNA synthetase inhibitor with activity against Pseudomonas aeruginosa publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02122-18 contributor: fullname: Kumar – ident: 10.1016/j.bmc.2022.116748_b0265 doi: 10.1111/bcp.14208 – volume: 10 start-page: 2473 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0395 article-title: Challenges and Limitations of Anti-quorum Sensing Therapies publication-title: Front Microbiol doi: 10.3389/fmicb.2019.02473 contributor: fullname: Krzyżek – volume: 35 start-page: 172 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0135 article-title: Crisaborole: a novel nonsteroidal topical treatment for atopic dermatitis publication-title: J Pharm Technol doi: 10.1177/8755122519844507 contributor: fullname: McDowell – volume: 1 start-page: 310 year: 2015 ident: 10.1016/j.bmc.2022.116748_b0520 article-title: 4, 5-Disubstituted 6-aryloxy-1, 3-dihydrobenzo [c][1, 2] oxaboroles are Broad-Spectrum Serine β-Lactamase Inhibitors publication-title: ACS Infect Dis doi: 10.1021/acsinfecdis.5b00031 contributor: fullname: McKinney – volume: 57 start-page: 1394 year: 2013 ident: 10.1016/j.bmc.2022.116748_b0535 article-title: Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02058-12 contributor: fullname: Hernandez – volume: 115 start-page: 9616 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0710 article-title: Clinical and veterinary trypanocidal benzoxaboroles target CPSF3 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.1807915115 contributor: fullname: Wall – volume: 53 start-page: 12532 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0340 article-title: Fluorogenic diazaborine formation of semicarbazide with designed coumarin derivatives publication-title: ChemComm contributor: fullname: Cambray – volume: 10 start-page: 2538 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0460 article-title: Pharmacological inhibitors of the NLRP3 inflammasome publication-title: Front Immunol doi: 10.3389/fimmu.2019.02538 contributor: fullname: Zahid – volume: 37 start-page: 35 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0655 article-title: Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology–phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells publication-title: Invest New Drugs doi: 10.1007/s10637-018-0611-z contributor: fullname: Psurski – volume: 854 start-page: 194 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0420 article-title: In vitro anti-glioblastoma activity of L-valine derived boroxazolidones publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2019.04.020 contributor: fullname: Viswanathan – volume: 71 start-page: 1521 year: 2015 ident: 10.1016/j.bmc.2022.116748_b0310 article-title: Crystallographic insights into the structure-activity relationships of diazaborine enoyl-ACP reductase inhibitors publication-title: Acta Crystallogr F Struct Biol Commun doi: 10.1107/S2053230X15022098 contributor: fullname: Jordan – volume: 23 start-page: 2038 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0555 article-title: Cinnamoyl-oxaborole amides: Synthesis and their in vitro biological activity publication-title: Molecules doi: 10.3390/molecules23082038 contributor: fullname: Gumbo – volume: 15 start-page: 1503 year: 2014 ident: 10.1016/j.bmc.2022.116748_b0185 article-title: Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71125-8 contributor: fullname: Kumar – volume: 798 start-page: 125 year: 2015 ident: 10.1016/j.bmc.2022.116748_b0660 article-title: Synthesis and evaluation of functionalized aminobenzoboroxoles as potential anti-cancer agents publication-title: J Organomet Chem doi: 10.1016/j.jorganchem.2015.06.021 contributor: fullname: Suman – volume: 28 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0760 article-title: Synthesis, characterization, antimicrobial activity, and QSAR studies of some new 6-substituted phenyl 3-(4-chlorophenyl)-3a, 4, 8, 8a-tetrahydro-[1, 3, 2] dioxaborepino [5, 6-d] isoxazoles publication-title: Heteroat Chem doi: 10.1002/hc.21363 contributor: fullname: Pir – volume: 53 start-page: 239 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0200 article-title: Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis publication-title: Drugs Today doi: 10.1358/dot.2017.53.4.2604174 contributor: fullname: Paton – volume: 21 start-page: 838 year: 2007 ident: 10.1016/j.bmc.2022.116748_b0070 article-title: Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma publication-title: Leukemia doi: 10.1038/sj.leu.2404528 contributor: fullname: Bonvini – volume: 8 start-page: 377 year: 1971 ident: 10.1016/j.bmc.2022.116748_b0275 article-title: Antibacterial borazaro derivatives. I. 5-Arylsulphonyl-4-hydroxy-4, 5-borazarothieno (2, 3-c) pyridines and 6-arylsulphonyl-7-hydroxy-7, 6-borazarothieno (3, 2-c) pyridines publication-title: Acta Pharm Suec contributor: fullname: Gronowitz – volume: 10 start-page: 217 year: 2016 ident: 10.1016/j.bmc.2022.116748_b0075 article-title: Spotlight on ixazomib: potential in the treatment of multiple myeloma publication-title: Drug Des. Devel contributor: fullname: Muz – volume: 57 start-page: 1902 year: 2014 ident: 10.1016/j.bmc.2022.116748_b0640 article-title: Discovery of a potent boronic acid derived inhibitor of the HCV RNA-dependent RNA polymerase publication-title: J Med Chem doi: 10.1021/jm400317w contributor: fullname: Maynard – start-page: 2015 year: 2015 ident: 10.1016/j.bmc.2022.116748_b0080 article-title: Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling publication-title: Biomed Res Int contributor: fullname: Accardi – volume: 23 start-page: 479 year: 2009 ident: 10.1016/j.bmc.2022.116748_b0150 article-title: Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4) publication-title: Best Pract Res Clin Endocrinol Metab doi: 10.1016/j.beem.2009.03.004 contributor: fullname: Thornberry – volume: 28 start-page: 3676 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0685 article-title: A hit deconstruction approach for the discovery of fetal hemoglobin inducers publication-title: Bioorganic Med Chem Lett doi: 10.1016/j.bmcl.2018.10.032 contributor: fullname: Benowitz – volume: 6 start-page: 173 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0750 article-title: Macrofilaricidal Benzimidazole-Benzoxaborole Hybrids as an Approach to the Treatment of River Blindness: Part 1. Amide Linked Analogs publication-title: ACS Infect. Dis doi: 10.1021/acsinfecdis.9b00396 contributor: fullname: Akama – volume: 20 year: 2014 ident: 10.1016/j.bmc.2022.116748_b0140 article-title: A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology publication-title: Dermatol Online J doi: 10.5070/D3205022608 contributor: fullname: Moustafa – volume: 32 start-page: 452 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0585 article-title: Two approaches to the use of benzo [c][1, 2] oxaboroles as active fragments for synthetic transformation of clarithromycin publication-title: J Enzyme Inhib Med Chem doi: 10.1080/14756366.2016.1261129 contributor: fullname: Lapa – volume: 274 start-page: 2107 year: 1996 ident: 10.1016/j.bmc.2022.116748_b0285 article-title: A mechanism of drug action revealed by structural studies of enoyl reductase publication-title: Science doi: 10.1126/science.274.5295.2107 contributor: fullname: Baldock – volume: 21 start-page: 660 year: 2013 ident: 10.1016/j.bmc.2022.116748_b0765 article-title: Synthesis and evaluation of thiazolidinedione and dioxazaborocane analogues as inhibitors of AI-2 quorum sensing in Vibrio harveyi publication-title: Bioorg Med Chem doi: 10.1016/j.bmc.2012.11.055 contributor: fullname: Brackman – volume: 316 start-page: 1759 year: 2007 ident: 10.1016/j.bmc.2022.116748_b0620 article-title: An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site publication-title: Science doi: 10.1126/science.1142189 contributor: fullname: Rock – volume: 124 start-page: 1038 year: 2014 ident: 10.1016/j.bmc.2022.116748_b0180 article-title: Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients publication-title: Blood, J Am Soc Hematol contributor: fullname: Richardson – volume: 8 start-page: 401 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0060 article-title: Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma publication-title: J Adv Pract Oncol. contributor: fullname: Ramirez – volume: 90 start-page: 451 year: 2021 ident: 10.1016/j.bmc.2022.116748_b0040 article-title: Progress in the medical chemistry of organoboron compounds publication-title: Russ Chem Rev doi: 10.1070/RCR4977 contributor: fullname: Tevyashova – volume: 379 start-page: 8 year: 2021 ident: 10.1016/j.bmc.2022.116748_b0045 article-title: Merging Boron with Nitrogen-Oxygen Bonds: A Review on BON publication-title: Heterocycles contributor: fullname: Golovanov – volume: 80 start-page: 1007 year: 2007 ident: 10.1016/j.bmc.2022.116748_b0405 article-title: In vitro apoptotic activity of 2, 2-diphenyl-1, 3, 2-oxazaborolidin-5-ones in L5178Y cells publication-title: Life Sci doi: 10.1016/j.lfs.2006.11.034 contributor: fullname: Velasco – volume: 14 start-page: 659 year: 2007 ident: 10.1016/j.bmc.2022.116748_b0425 article-title: Elemental isomerism: A boron-nitrogen surrogate for a carbon-carbon double bond increases the chemical diversity of estrogen receptor ligands publication-title: Chem Biol doi: 10.1016/j.chembiol.2007.04.009 contributor: fullname: Zhou – volume: 62 start-page: e02419 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0735 article-title: Topical treatment for cutaneous leishmaniasis: dermato-pharmacokinetic lead optimization of benzoxaboroles publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.02419-17 contributor: fullname: Van Bocxlaer – volume: 81 start-page: 59 year: 2014 ident: 10.1016/j.bmc.2022.116748_b0745 article-title: Novel pyrrolobenzoxaboroles: Design, synthesis, and biological evaluation against Trypanosoma brucei publication-title: Eur J Med Chem doi: 10.1016/j.ejmech.2014.04.079 contributor: fullname: Wu – volume: 16 start-page: 157 year: 2007 ident: 10.1016/j.bmc.2022.116748_b0120 article-title: Recent progress on the topical therapy of onychomycosis publication-title: Expert Opin Invest Drugs doi: 10.1517/13543784.16.2.157 contributor: fullname: Alley – volume: 3 start-page: 1 year: 2013 ident: 10.1016/j.bmc.2022.116748_b0615 article-title: Discovery of a potent benzoxaborole-based anti-pneumococcal agent targeting leucyl-tRNA synthetase publication-title: Sci Rep doi: 10.1038/srep02475 contributor: fullname: Hu – volume: 58 start-page: 5445 year: 2015 ident: 10.1016/j.bmc.2022.116748_b0725 article-title: Click chemistry in lead optimization of boronic acids as β-lactamase inhibitors publication-title: J Med Chem doi: 10.1021/acs.jmedchem.5b00341 contributor: fullname: Caselli – volume: 10 start-page: 1205 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0695 article-title: Bis-benzoxaboroles: Design, Synthesis, and Biological Evaluation as Carbonic Anhydrase Inhibitors publication-title: ACS Med Chem Lett doi: 10.1021/acsmedchemlett.9b00252 contributor: fullname: Larcher – volume: 76 start-page: 160 year: 2021 ident: 10.1016/j.bmc.2022.116748_b0090 article-title: Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkaa391 contributor: fullname: Mushtaq – volume: 10 start-page: 1 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0455 article-title: Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors publication-title: Cell Death Dis contributor: fullname: Yang – volume: 8 start-page: 1 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0720 article-title: A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue publication-title: Nat Commun doi: 10.1038/ncomms14574 contributor: fullname: Sonoiki – volume: 2007 start-page: 0921 year: 2007 ident: 10.1016/j.bmc.2022.116748_b0410 article-title: Preparation of apoptotic inducers, 2, 2-diphenyl-1, 3, 2-oxazaborolidin-5-ones, under alkaline conditions publication-title: Synlett doi: 10.1055/s-2007-973886 contributor: fullname: Velasco-Bejarano – volume: 108 start-page: 96 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0560 article-title: The 7-phenyl benzoxaborole series is active against Mycobacterium tuberculosis publication-title: Tuberculosis doi: 10.1016/j.tube.2017.11.003 contributor: fullname: Korkegian – volume: 274 start-page: 30811 year: 1999 ident: 10.1016/j.bmc.2022.116748_b0295 article-title: Inhibitor binding studies on enoyl reductase reveal conformational changes related to substrate recognition publication-title: J Biol Chem doi: 10.1074/jbc.274.43.30811 contributor: fullname: Roujeinikova – volume: 7 start-page: 20620 year: 2017 ident: 10.1016/j.bmc.2022.116748_b0415 article-title: Base catalysed N-functionalisation of boroxazolidones publication-title: RSC Adv doi: 10.1039/C7RA03266H contributor: fullname: Raunio – volume: 108 start-page: 12 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0130 article-title: Examining the benefits of the boron-based mechanism of action and physicochemical properties of tavaborole in the treatment of onychomycosis publication-title: J Am Podiatr Med Assoc doi: 10.7547/16-154 contributor: fullname: Markinson – volume: 64 start-page: e01963 year: 2020 ident: 10.1016/j.bmc.2022.116748_b0110 article-title: VNRX-5133 (taniborbactam), a broad-spectrum inhibitor of serine-and metallo-β-lactamases, restores activity of cefepime in Enterobacterales and Pseudomonas aeruginosa publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01963-19 contributor: fullname: Hamrick – ident: 10.1016/j.bmc.2022.116748_b0170 – volume: 59 start-page: 289 year: 2015 ident: 10.1016/j.bmc.2022.116748_b0540 article-title: Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.03774-14 contributor: fullname: O'Dwyer – volume: 17 start-page: 683 year: 2019 ident: 10.1016/j.bmc.2022.116748_b0575 article-title: Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer publication-title: Org Biomol Chem doi: 10.1039/C8OB02668H contributor: fullname: Lei – volume: 102 start-page: 4639 year: 2002 ident: 10.1016/j.bmc.2022.116748_b0325 article-title: Irreversible inhibitors of serine, cysteine, and threonine proteases publication-title: Chem Rev doi: 10.1021/cr010182v contributor: fullname: Powers – volume: 25 start-page: 1794 year: 2016 ident: 10.1016/j.bmc.2022.116748_b0375 article-title: Synthesis, characterization, antimicrobial activity, and QSAR studies on substituted oxadiazaboroles publication-title: Med Chem Res doi: 10.1007/s00044-016-1603-1 contributor: fullname: Pir – volume: 84 start-page: 4680 year: 2018 ident: 10.1016/j.bmc.2022.116748_b0645 article-title: Convergent synthesis of the NS5B inhibitor GSK8175 enabled by transition metal catalysis publication-title: J Org Chem doi: 10.1021/acs.joc.8b02269 contributor: fullname: Arrington – volume: 12 start-page: 431 year: 2011 ident: 10.1016/j.bmc.2022.116748_b0165 article-title: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70081-X contributor: fullname: Moreau – ident: 10.1016/j.bmc.2022.116748_b0195 |
| SSID | ssj0002491 |
| Score | 2.5754416 |
| SecondaryResourceType | review_article |
| Snippet | [Display omitted]
The incorporation of the “magic” boron atom has been established as an important new strategy in the field of medicinal chemistry as boron... The incorporation of the "magic" boron atom has been established as an important new strategy in the field of medicinal chemistry as boron compounds have been... |
| SourceID | proquest crossref pubmed elsevier |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 116748 |
| SubjectTerms | Azaborines Benzoxaboroles Boron - chemistry Boron - pharmacology Boron containing Drugs Boron Containing Heterocycles Bortezomib Chemistry, Pharmaceutical Diazaborines Oxadiazaboroles Oxazaborolidines Oxazoborolidine-ones Pharmacological agents |
| Title | Boron-Containing heterocycles as promising pharmacological agents |
| URI | https://dx.doi.org/10.1016/j.bmc.2022.116748 https://www.ncbi.nlm.nih.gov/pubmed/35453036 https://search.proquest.com/docview/2654293648 |
| Volume | 63 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEB58gHoRbX1rWUE8CLHdzb56rEWpSr1owVvIExXcFlsPXvztzmR3FUE9eNzdhA3fJDOTzJcZgKOu61hnjGOZMQmLtesy5ZRjWmY81Vxb7cmYw5t0MIqv7pP7OejXd2GIVlnp_lKne21dvWlXaLYnj4_tW3S-807eTaPIJ4nJ5mERzRHFahd7l9eDm0-FjDsMXzgP2zPqUAc3Pc1LPVMiwyg6pYAEVQH62Tz95n56M3SxBquV_xj0yiGuw5wtGtDsFbh3fn4LjgPP6PRH5Q1Y7tfV3BqwNKyC6E3onVHWAkZ5qcryEMEDcWLG-o0YcoGcBjgK7EdfJl-ZrUmagaSbWNMNGF2c3_UHrKqkwDRP-IwZXGk8tJnRMdr3REYulkkqY2dTOhZ2aZ4Zp8KQW2nzNJbSmjJAaw26ADbkm7BQjAu7DYGVStHtU-VyjaKNFG7i4sii56Jx6Su9Ayc1gGJSJswQNZPsSSDagtAWJdo7ENcQi29SF6jQ_-p2WItDIBwU4pCFHb9OReTrb_GU2myVcvocBUdnkQz27v9-ugcr9FTSxPZhYfbyag_QIZmpFsyfvoetatp9AFMr3wY |
| link.rule.ids | 314,780,784,4502,24116,27924,27925,45585,45679 |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEB58gHoRre_nCuJBiLWb7KPHWpT6qBcVvIU8UcFtsfXgxd_uTHZXEdSD103Chplk5kvmywzAftsfO2-tZ5m1CRPGt5n22jOjMp4abpwJZMz-ddq7Exf3yf0EdOu3MESrrGx_adODta6-NCtpNoePj80bBN_5cd5O4zgkickmYVokiH5xUR-9f_E88HwRyuZhb0bd69BmIHnpZ0pjGMdHFI6gGkA_O6ffwGdwQmcLMF-hx6hTTnARJlzRgKVOgSfn57foIAp8znBR3oDZbl3LrQEz_SqEvgSdE8pZwCgrVVkcInogRszAvBE_LlKjCGeB46hl-JXXmnQZKXqHNVqGu7PT226PVXUUmOEJHzOL-4y3XGaNQO-eqNgLlaRKeJfSpbBP88x63Wpxp1yeCqWcLcOzziIAcC2-AlPFoHBrEDmlNb091T43qNhY4xFOxA5xi8GNr806HNYClMMyXYaseWRPEqUtSdqylPY6iFrE8pvOJZrzv4bt1eqQKA4KcKjCDV5HMg7Vt3hKfVZLPX3OgiNUJHe98b-f7sJs77Z_Ja_Ory83YY5aSsLYFkyNX17dNkKTsd4JS-8DUlrf3w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Boron-Containing+heterocycles+as+promising+pharmacological+agents&rft.jtitle=Bioorganic+%26+medicinal+chemistry&rft.au=Das%2C+Bhaskar+C&rft.au=Adil+Shareef%2C+Mohammed&rft.au=Das%2C+Sasmita&rft.au=Nandwana%2C+Nitesh+K&rft.date=2022-06-01&rft.eissn=1464-3391&rft.volume=63&rft.spage=116748&rft_id=info:doi/10.1016%2Fj.bmc.2022.116748&rft_id=info%3Apmid%2F35453036&rft.externalDocID=35453036 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0968-0896&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0968-0896&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0968-0896&client=summon |